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Abstract 
	
Joubert syndrome (JBTS) is a genetically heterogeneous neurodevelopmental 
ciliopathy that can have severe renal manifestations requiring renal replacement 
therapy. JBTS can be caused by mutation in 34 genes, however more than 50% of 
JBTS cases have unknown genetic causes. Through a multidisciplinary renal-
genetics family clinic we studied a cohort of patients with inherited renal disorders 
and identified two families with JBTS phenotype and unknown molecular genetic 
diagnosis. We further investigated the underlying genetic aetiology of Joubert 
syndrome using combined homozygosity mapping of both families highlighted a 
candidate locus on chromosome 10, and whole exome sequencing revealed two 
missense variants in ARL3 within the candidate locus. The encoded protein, ADP 
ribosylation factor-like GTPase 3 (ARL3), is a small GTP-binding protein that is 
involved in trafficking lipid-modified proteins into the cilium in a GTP-dependent 
manner. Both missense variants replace the highly conserved Arg149 residue, which 
we show to be necessary for the interaction with its guanine nucleotide exchange 
factor ARL13B. Using patients derived fibroblasts, we identified that the mutant 
ARL3 protein is associated with reduced ciliary cargo protein INPP5E and NPHP3 
localization in cilia.  
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Chapter 1 Introduction  
1.1. Inherited kidney disorders 
Inherited kidney disorders are classified as rare disorders, which affect a limited 
number of individuals, defined as affecting <1 in 2000 people in Europe or < 1 in 200 
000 people in the USA (Schieppati et al., 2008). Rare kidney disorders include at 
least 150 different diseases with an overall prevalence of about 60-80 cases per 100 
000 in Europe and the USA (Soliman, 2012). Inherited disorders have a well-
recognised medical, psychosocial and economic burden on the affected families, as 
well as providing challenges for health care providers. Inherited kidney disorders, 
especially cystic kidney disease, are often known to cause chronic kidney disease 
progressing to end stage renal disease (ESRD) requiring dialysis or renal 
transplantation in both children and adult populations. Due to the recent advances in 
renal replacement therapy, individuals with inherited kidney disorders rarely die due 
to ESRD, however they experience a very poor quality of life.  
Kidneys are vital organs, complex, highly specialised and target organs for diseases. 
The kidneys central role is in controlling body homeostasis, its excretory, metabolic 
and endocrine functions directly arbitrates essential interactions with other organs 
(Eckardt et al., 2013). The nephron is the functional unit of the kidney; each kidney is 
made of about one million nephrons. This highly specialised unit contains a filtration 
segment, the glomerulus, and renal tubules whose distal segments form collecting 
ducts that open in the renal pelvis. Kidney disease can originate from any segment 
of the nephron, and abnormal kidney function can manifest in several extra renal 
phenotypes (Devuyst et al., 2014).  
 
1.2. The role of next generation sequencing (NGS) in identifying the genetic 
cause of inherited kidney disorders 
Genetic research into inherited kidney disorders goes back to 1980s when the 
causative gene of autosomal dominant polycystic kidney disease (ADPKD) was first 
mapped to chromosome 16 in 1985 (Reeders et al., 1985). This was followed by the 
detection of 3 different point mutations at specific locus in COL4A5 gene causing the 
kidney disorder Alport’s syndrome (Barker et al., 1990). The year 2010 marked the 
  
2 
 
first success of exome sequencing in inherited kidney disorders, when Otto et al. 
(2010) used an approach of combining homozygosity mapping with whole exome 
sequencing (WES), identifying mutations of SDCCAG8 as the cause of retinal-renal 
ciliopathy (Senior-Løken syndrome). Next-generation sequencing (NGS) techniques 
became the preferable approach in inherited kidney disorders research and have 
improved the diagnostic efficiency. Examples of effective applications of NGS were 
reported for nephronophthisis genes analysis using DNA pooling and NGS (Otto et 
al., 2011). Multigene panels were successfully used in the diagnostic screening of 
Alport syndrome (Artuso et al., 2012). The application of NGS in the current clinical 
and genetic practice has increased the number of new genes identified to cause 
inherited kidney diseases. However, this technology requires accurate and reliable 
pool of databases that allow an assessment of the pathogenicity and population 
frequency of variants and the use of different disease models to determine the 
identified gene causality. 
NGS technology gives more breadth to the number of genetic tests that can be 
efficiently performed, which by itself is meaningless if not combined with detailed and 
accurate phenotypic data attained by the clinicians. An informative diagnostic 
approach in inherited kidney disease starts with detailed family history and 
investigation, a proper characterisation of the renal phenotype, thorough systematic 
investigation to identify extrarenal features, and confirmatory tests (Joly et al., 2015).   
There is no standard classification of inherited kidney disorders. Diseases may be 
grouped according to their main diagnostic features, grouped according to renal 
growth, structural or functional disorders, monogenic or polygenic disorders, or 
according to the presence or absence of systemic disease as primary or secondary 
kidney disorders (Hildebrandt, 2010, Eckardt et al., 2013, Devuyst et al., 2014). This 
study will focus on the investigation of inherited renal ciliopathies including the 
cerebello-retinal-renal syndrome called Joubert syndrome (JBTS). 
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1.3. Ciliopathies 
Cilia are ancient organelles projecting from the cell surface. Cilia are classified into 
two classes: motile and immotile cilia. Motile cilia are found in the cell lining of brain 
ventricles, respiratory tract, and the oviduct. The beating nature of motile cilia 
function as a driving force to circulate and direct fluid flow in ventricles and tracts. On 
the other hand, immotile cilia are (also known as primary cilia) were thought to be 
evolutionary remnants; lacking obvious function. Not until the past decade when it 
was discovered that primary cilia have vital role in many key signalling pathways 
essential for development and homoeostasis (Hildebrandt et al., 2011a).  
Ciliopathies are an emerging class of disorders that were recognised in the past 
decade by their unified underlying pathophysiology: dysfunction of the primary cilia 
(Badano et al., 2006). Dysfunction of any of protein complexes involved in the 
trafficking in and out or within the primary cilium interfere with its function and 
structure, giving rise to disorders that exhibit genetic and phenotypic heterogeneity 
(Waters and Beales, 2011). Ciliopathies are caused by mutations in more than 50 
genes with protein products located in or around the primary cilium leading to multi-
organ disorders affecting almost every major body system, starting with the brain, 
eyes, kidneys, liver, skeleton and ending with the limbs. Ciliopathies clinically and 
genetically overlap (Hildebrandt et al., 2011b). Table 1.1 lists the known ciliopathies 
to date, their phenotypes and genetic mutations, ordered alphabetically. 
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Ciliopathy Common Features Gene(s) 
Alstrom 
syndrome 
(ALSM) 
Dilated cardiomyopathy, 
obesity, sensory neural 
hearing loss, retinitis 
pigmentosa, endocrine 
abnormalities, renal and 
hepatic manifestations   
ALMS1 
Bardet-Biedl 
syndrome (BBS) 
Obesity, polydactyly, retinitis 
pigmentosa, anosmia, 
congenital heart defects 
BBS1, BBS2, BBS4, BBS5, 
BBS7, BBS9, BBS10, BBS12, 
ARL6, MKKS, TTC8, TRIM32, 
MKS1, CEP290, SDCCAG8, 
WDPCP, LZTFL1, PTHB1, 
C8orf37, IFT74, BBIP1, IFT27 
Ellis van Creveld 
syndrome (EVC) 
Skeletal dysplasia, 
congenital heart defect, 
polydactyly; ectodermal 
dysplasia  
EVC1, EVC2  
Jeune Syndrome 
(JS) 
Skeletal dysplasia, thoracic 
deformities, polydactyly, 
renal cysts, retinitis 
pigmentosa  
IFT80, DYNC2H1, CEP120, 
CSPP1, IFT140, IFT172, 
TTC21B, WDR19, WDR34, 
WDR35, WDR60 
Joubert 
syndrome 
(JBTS) 
Hypoplasia of the cerebellar 
vermis (molar tooth sign), 
dysregulated breathing 
pattern, retinal dystrophy, 
renal anomalies  
INPP5E, TMEM216, AHI1, 
NPHP1, CEP290, TMEM67, 
RPGRIP1L, ARL13B, 
CC2D2A, OFD1, KIF7, 
TCTN1-3, TMEM237, CEP41, 
TMEM138, ZNF423, 
TMEM231, CSPP1, PDE6D, 
CEP104, B9D1, MKS1, 
KIAA0586, ARMC9, 
CPLANE1, CEP120, SUFU, 
KATNIP, PIBF1, TMEM107, 
B9D2 
Leber congenital 
amaurosis 
(LCA) 
Early onset visual 
impairment (first year); 
pigmentary retinopathy  
GUCY2D, RPE65, SPATA7, 
AIPL1, LCA5, RPGRIP1, CRX, 
CRB1, NMNAT, CEP290, 
IMPDH1, RD3, RDH12, LRAT, 
TULP1, KCNJ13, GDF6, 
PRPH2 
Meckel–Gruber 
syndrome 
Renal cysts, CNS anomalies 
(encephalocele), 
MKS1, TMEM216, TMEM67, 
CEP290, RPGRIP1L, 
CC2D2A, B9D1, B9D2, 
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Ciliopathy Common Features Gene(s) 
(MKS)  polydactyly, congenital heart 
deformity,  
TMEM107, TCTN2, NPHP3, 
KIF14 
Nephronophthisis  
(NPHP) 
Renal fibrosis and renal 
cysts with or without extra-
renal manifestations 
NPHP1, INVS, NPHP3, 
NPHP4, IQCB1, CEP290, 
GLIS2, RPGRIP1L, NEK8, 
SDCCAG8, TMEM67, 
TTC21B, ANKS6, CEP83, 
CEP164, DCDC2, IFT72, 
WDR19, ZNF423, MAPKBP1, 
AHI1, CC2D2A, XPNPEP3, 
ATXN10, SLC41A1  
Oral-facial-digital 
syndrome type 1 
(OFD) 
Oral cavity, face and digit 
anomalies; CNS 
abnormalities; cystic kidney 
disease; linked with male 
lethality 
OFD1 
Polycystic 
Kidney disease 
(PKD) 
Renal cysts and extra-renal 
features  
PKHD1, PKD1, PKD2, 
SEC61A1, GANAB 
Senior-Løken 
syndrome (SLSN) 
Retinal dystrophy and 
nephronophthisis  
NPHP1, NPHP4, IQCB1, 
SLSN3, SDCCAG8, WDR19, 
TRAS3IP1 
Sensenbrenner 
syndrome (SS) 
Cranioectodermal dysplasia, 
narrow thorax, dental 
anomalies, hepatic and 
renal manifestations   
IFT122, WDR35, WDR19, 
IFT43 
Short rib 
polydactyly 
(SRP) 
Lethal skeletal dysplasia, 
polydactyly, congenital renal 
dysplasia, multiple 
congenital anomalies  
NEK1, DYNC2H1, TTC21B, 
KIAA0586 
 
Table 1.1 Summary of Ciliopathies, their common features and causative 
genes. 
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1.4. Renal manifestation of ciliopathies  
In the perspective of primary ciliary dysfunction, the disease can manifest in any 
organ predominantly in the kidneys, liver, eye, and brain. It can have developmental 
phenotype presenting at birth or later during childhood depending on the severity of 
the underlying mutation as well as number of disrupted ciliary proteins. Pazour et al. 
(2000) were the first to link ciliary disruption to the development of cystic kidney 
disease in mammals.  
The common and leading genetic cause of renal failure in paediatric and adult 
population are renal ciliopathies. The spectrum of renal phenotype in ciliopathies can 
be classified as polycystic, renal medullary cystic disease / nephronophthisis and 
cystic renal dysplasia. 
 
 
Figure 1.1 Kidney disease phenotypes seen in ciliopathies  
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1.4.1. Cystic kidney disease 
Polycystic kidney disease characterised by the presence of multiple cysts in the 
kidneys, liver or both and can be recognised in neonatal period or during childhood. 
PKD is a group of monogenic disorders can be inherited in an autosomal dominant 
manner or recessive manner (Harris, 2009). Autosomal polycystic kidney disease 
(ADPKD) is found to be caused by a mutation in genes including PKD1 encoding 
polycystin-1 (PC-1) and PKD2 encoding polycystin-2 (PC-2) (Hughes et al., 1995, 
Mochizuki et al., 1996). Two additional genes have recently been implicated in 
ADPKD and include GANAB and SEC61A1 (Porath et al., 2016, Bolar et al., 2016). 
Autosomal recessive polycystic kidney disease (ARPKD) is caused by homozygous 
or compound heterozygous mutations in PKHD1 encoding fibrocystin protein. PC-1, 
PC-2 and fibrocystin proteins are found to form a complex and localised at the 
primary cilia and the basal body in addition to various cellular sites (Yoder et al., 
2002, Ward et al., 2003). Table 1.3 summarises the clinical presentation and 
expected outcome of the polycystic kidney disease. 
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 ADPKD ARPKD 
onset 
Sometimes in utero or in Neonatal 
period, mostly 2nd and 3rd decade of 
life 
Utero or neonatal period, 
sometimes childhood or adulthood 
Incidence 1:400 – 1:1,000 1:20,000 
cysts 
Focal cysts along the nephron, 
mostly collecting duct 
Fusiform dilatation of the collecting 
ducts 
Signs and 
symptoms 
Bilaterally enlarged kidneys, loin 
pain, renal colic, haematuria, UTI 
and hypertension 
Bilaterally enlarged kidneys, loin 
pain, renal colic, haematuria, UTI 
and (severe) hypertension 
Morbidity 
and 
mortality 
Ruptured intracranial artery 
aneurysm 
Adulthood onset ESRD 
Childhood onset ESRD 
Renal transplant in 30% 
Other 
organs 
involved 
Cysts in liver, pancreas and seminal 
vesicles 
Congenital fibrocystic liver, portal 
hypertension, oesophageal varices 
and cholangitis 
Table 1.3 Clinical summary of polycystic kidney diseases 
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1.4.2. Nephronophthisis 
Nephronophthisis (NPHP) is an autosomal recessive inherited monogenic kidney 
disorder, which literally means “damage to the nephrons” (Arts and Knoers, 2013). 
NPHP manifests in progressive loss of renal function causing ESRD before the age 
of 30 years old (Simms et al., 2009). NPHP can be caused by more than 20 genes 
all were found to encode proteins localised to the centrosome and the primary cilia, 
and up to date list of genes are summarised in Table 1.4 (Srivastava et al., 2018). 
NPHP is characterised by fibrotic tubule interstitial and a subsequent formation of 
renal cysts at the corticomedullary junction, such pathology cause depletion in 
glomerular filtration rate (GFR) and loss of distal tubules function. Clinical symptoms 
include polyuria, polydipsia, secondary enuresis, growth retardation and ESRD 
eventually (Hildebrandt et al., 2009).  
Extrarenal manifestation can be associated with NPHP in 20% of cases, giving rise 
to different additional phenotypes of ciliopathies including Senior–Løken syndrome, 
Alstrom syndrome, Arima syndrome, Cogan syndrome, Joubert syndrome, Bardet-
Biedl syndrome, Jeune syndrome, Sensenbrenner syndrome, Ellis-van Creveld 
syndrome and Saldino-Mainzer syndrome. NPHP extra renal involvements are 
retinopathy, cerebral vermis hypoplasia, intellectual disability, oculomotor apraxia, 
hepatobiliary disease, laterality defects and skeletal dysplasia (Salomon et al., 
2009).  
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HGCN 
symbol 
NPHP 
Type 
Disorders Key insights 
NPHP1 NPHP1 NPHP/SLSN/ 
JBTS 
Cell-cell junction and ciliary transition zone 
protein 
INVS NPHP2 NPHP/SLSN Role in wnt signaling 
NPHP3 NPHP3 NPHP/SLSN/ 
MKS 
Murine model pcy has a hypomorphic Nphp3 
allele 
NPHP4 NPHP4 NPHP/SLSN Role in both cilia and cell-junctions 
IQCB1 NPHP5 SLSN/LCA Localises to connecting cilium of 
photoreceptor cells 
CEP290 NPHP6 JBTS/BBS/MKS/ 
LCA/SLSN 
Centrosomal protein 
GLIS2 NPHP7 NPHP Increase in apoptosis and fibrosis in murine 
model Glis2 
RPGRIP1L NPHP8 JBTS/MKS Ciliary transition zone protein and facilitates 
vesicular docking of ciliary proteins 
NEK8 NPHP9 NPHP Links cilia and cell cycle defects in NPHP 
SDCCAG8 NPHP10 SLSN/BBS Implicates DNA damage and NPHP 
TMEM67 NPHP11 NPHP/MKS/JBTS Required for ciliogenesis 
TTC21B NPHP12 NPHP/JS IFT protein 
WDR19 NPHP13 NPHP/CED/JS IFT protein 
ZNF423 NPHP14 JBTS Centrosomal protein and role in DNA repair 
signaling 
CEP164 NPHP15 NPHP/SLSN/ 
JBTS 
Centrosomal protein and role in DNA repair 
signaling 
ANKS6 NPHP16 NPHP Functional module with INVS and NPHP3 
AHI1 JBTS3 NPHP/JBTS Important for cerebellar development 
XPNPEP3 NPHPL1 NPHP Mitochondrial defect linking ciliopathies with 
mitochondria and potential novel pathways of 
disease. 
ATXN10 N/A NPHP/SCA Interacts with NPHP5 
SLC41A1 N/A NPHP-Like Renal Magnesium transporter defect 
CEP83 N/A NPHP Component of distal appendages of centriole 
MAPKBP1 NPHP20 NPHP Non-ciliary protein, involved in JNK signaling 
Table 1.4 Genetic classification of Nephronophthisis, its related disorders and 
key insights. Obtained from (Srivastava et al., 2018). 
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1.4.3. Renal dysplasia  
Ciliary dysfunction can be associated with other severe forms of kidney diseases. 
Meckel-Gruber syndrome is perinatally lethal and characterised by neural tube 
defect, polydactyly, bile duct proliferation and cystic renal dysplasia (Alexiev et al., 
2006). This condition is caused by mutation in many genes encoding centrosomal 
and ciliary proteins. Another severe condition is the short-rib-polydactyly syndrome, 
a lethal skeletal ciliopathy, which exhibits congenital renal dysplasia (Thiel et al., 
2011, Merrill et al., 2009). Gross kidney abnormalities have been reported in 
ciliopathies like horseshoe kidneys, lobulated kidneys as well as to urinary tract 
anomalies (Bergmann, 2012). in ciliopathies, the presence of asymmetrical renal 
disease is unexpected, however, unilateral multicystic dysplastic kidney were 
reported in few cases of JBTS (Fleming et al., 2017, Malaki et al., 2012).   
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1.5. Joubert Syndrome 
Joubert syndrome (JBTS) is a neurodevelopmental ciliopathy with recessive 
inheritance causing cerebellar vermis hypoplasia (Joubert et al., 1969). The core of 
JBTS is the neurological phenotype appearing soon after birth, characterised by 
hypotonia, abnormal eye movement (oculomotor apraxia), intellectual disability, 
truncal ataxia, and respiratory control dysfunction (sleep apnoea) (Boltshauser and 
Isler, 1977). The neurological symptoms are still nonspecific and the hallmark of 
JBTS is the presence of “The Molar Tooth sign” on the axial brain MRI imaging 
(Poretti et al., 2014b). This pathognomonic feature was first described by Maria et al. 
(1997) arises from the hypoplasia and the dysplasia of the cerebellar vermis and of 
pontine and medullary structure, as well as the absence of decussation of the 
superior cerebellar peduncles and the pyramidal tracts. JBTS presentation can be 
purely neurological, patients present early in life with hypotonia, abnormal eye 
movement (includes: oculomotor apraxia, nystagmus, and strabismus), respiratory 
control dysfunction that alternate between sleep apnoea and tachypnoea or 
episodes of tachypnoea alone (Saraiva and Baraitser, 1992). Later in life, children 
acquire developmental delay, they might experience delayed speech (expressive 
and comprehensive) delayed walking, broad-based ataxia and difficulty in running 
and climbing.  Intellectual disability and cognitive impairment seen nearly in all cases 
of JBTS with variable severity (Doherty, 2009).  However, the cases can be 
complicated by the extra neurological manifestations, which range in severity. 
Therefore, patients diagnosed with JBTS undergo diagnostic examination and 
regular follow-up to assess and manage their multi-organ manifestations.  
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Figure 1.2 Brain magnetic resonance images (MRI) showing diagnostic 
findings of Joubert syndrome (JBTS) in comparison to normal findings.  
(a) Axial brain MRI obtained at the level of the junction of the midbrain and pons 
showing the “molar tooth sign” (circle) and hypoplastic cerebellar vermis (arrows) in 
comparison to normal (c). (b) Sagittal brain MRI demonstrating hypoplasia of the 
cerebellar vermis (circle) and enlarged fourth ventricle (asterisk) in comparison to 
normal (d). Image taken from (Vilboux et al., 2017) 
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1.6. The extra neurological manifestations of Joubert syndrome  
About 20-40% of JBTS patients develop renal involvement at any age in the form of 
nephronophthisis or cystic dysplastic kidneys, ocular involvement including 
chorioretinal coloboma, retinal dystrophy and blindness, hepatic involvement such as 
ductal plate malformation and fibrosis, dysmorphic facial features and/or skeletal 
involvement like dystrophy or polydactyly (Romani et al., 2013). Parisi et al. (2007) 
proposed a JBTS subtypes based on the presence or the absence of multiorgan 
involvement features to: Pure JBTS, JBTS with retinal involvement, JBTS with renal 
involvement, JBTS with liver involvement and JBTS with oral-facial –digital features.   
1.6.1. Ocular features  
The most common extra neurological involvements are ocular and oculomotor 
abnormalities. Eye movements abnormalities are seen in between 70-100% of JBTS 
patients including oculomotor apraxia, nystagmus, strabismus, and vertical gaze 
palsy (Pellegrino et al., 1997). The retinal defects were found to affect 30% of JBTS 
patients (Bachmann-Gagescu et al., 2015). Progressive photoreceptors 
degeneration found to be the leading cause of retinal dystrophy. The clinical 
presentation varies in severity and spectrum can range from congenital blindness to 
slowly progressing retinal dystrophy with persevered partial vision (Lambert et al., 
1989).  
1.6.2. Renal features  
 The renal defects are present in almost one quarter of JBTS cases (Valente et al., 
2013b). Two major forms of kidney diseases were reported in JBTS:  juvenile 
nephronophthisis and cystic dysplastic kidneys. Juvenile NPHP characterised by 
microscopic cysts formation at the cortico-medullary junction of the kidneys, affecting 
the ability of kidney to concentre urine and conserve sodium. Presenting with 
polydipsia and polyuria in early life with normal glomerular filtration rate (GFR) 
(Salomon et al., 2009). As the disease progress, renal insufficiency occurs 
manifesting in anaemia and growth retardation and subsequently developing end 
stage renal disease (ESRD) at early teens. In a recent cohort of JBTS patient, 30% 
of cases were found to be associated with NPHP (Fleming et al., 2017). On the other 
hand, JBTS with cystic kidney dysplasia characterised by the presence of multiple 
cysts with variable sizes in foetal kidney or at birth known as Dekaban–Arima 
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syndrome (Dekaban, 1969). Comorbidity of retinal and renal involvement have been 
noted, with all JBTS patients with renal disease had retinopathy (Saraiva and 
Baraitser, 1992, Boltshauser et al., 1995, Brancati et al., 2007, Bachmann-Gagescu 
et al., 2015). 
1.6.3. Hepatic features 
The association of JBTS with liver disease known by the acronym COACH standing 
for Cerebellar vermis hypoplasia, Oligophrenia, Ataxia, Coloboma and Hepatic 
fibrosis (Satran et al., 1999). This congenital hepatic fibrosis (CHF) results from 
ductal plate embryonic malformation associated with cystic dilatation of primitive 
biliary structures and fibrous enlargement of the portal tracts. JBTS individuals may 
present with elevated liver enzymes and hepatomegaly. In some cases, patient can 
develop portal hypertension, oesophageal varices or liver cirrhosis (Gleeson et al., 
2004). A very strong association has been established between the presence of 
coloboma and hepatic fibrosis in JBTS patients (Brancati et al., 2009, Doherty et al., 
2010, Bachmann-Gagescu et al., 2015). 
1.6.4. Skeletal features 
Polydactyly has been reported in around 15% of JBTS cases (Brancati et al., 2010) 
as well as in the first case of reported JBTS (Joubert et al., 1969). Oral defect can 
present alongside polydactyly in a condition known as oral-facial-digital type VI 
syndrome (Poretti et al., 2008). A late manifestation of early infancy hypotonia is the 
development of mild to severe scoliosis, which requires a close monitoring especially 
during puberty. 
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1.7. The molecular genetic causes of Joubert syndrome  
Like other ciliopathies, JBTS exhibits noticeable genetic heterogeneity. It is caused 
by recessive mutations in more than 30 genes (OMIM phenotypic series PS213300) 
which are known to encode proteins localised to the primary cilium and its basal 
body. Yet those identified genes explain the causative mutation in only 40-50% of 
JBTS cases (Valente et al., 2013b). Finding the correct molecular diagnosis provides 
accurate genetic counselling in families with JBTS child, predicting prognosis, family 
planning and prenatal diagnosis. Next generation sequencing (NGS), particularly 
whole exome sequencing (WES) studies, was a useful tool based on the complexity 
and heterogeneity of the disease to determine the genotype-phenotype correlation of 
JBTS, and equally identifying novel causative gene mutations.  
1.7.1. JBTS#1: INPP5E 
JBTS#1 is caused by homozygous or compound heterozygous mutations in INPP5E 
on chromosome 9q34 (Bielas et al., 2009). INPP5E encodes inositol polyphosphate-
5-phosphatase (INPP5E) known to be exclusively localised in primary cilia, 
specifically the axoneme, of different cell types. Mutation in INPP5E often disrupt the 
catalytic domain of the protein decreasing its phosphatase activity leading to 
impaired phosphotidylinositol (ptdIns) signalling thus affecting the primary cilia role in 
mediating cell signals and neuronal function. JBTS1 patients reported retinopathy 
and colobomas as common extra neural manifestation, while 10% of JBTS1 patient 
may develop renal disease (Kroes et al., 2016). Mutation in INPP5E can also cause 
MORM an acronym for mental retardation, truncal obesity, retinal dystrophy, and 
micropenis syndrome (Bielas et al., 2009). 
1.7.2. JBTS#2: TMEM216 
JBTS#2 is caused by homozygous or compound heterozygous mutations in the 
TMEM216 gene on chromosome 11q12 (Keeler et al., 2003). It encodes tetraspan 
transmembrane protein (TMEM216) that is localised to the base of the cilia and 
regulates signalling and trafficking of its partner proteins. TMEM216 mutation affects 
ciliogenesis and docking of centrosomes. In addition to the neurological features 
JBTS2 patients had retinopathy, colobomas, polydactyly, and nephronophthisis. 
Some cases reported other miscellaneous features such as patent foramen oval and 
Dandy-Walker malformation. TMEM216 mutation causing JBTS2 in Ashkenazi 
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Jewish population (Edvardson et al., 2010, Valente et al., 2010). Mutation in the 
TMEM216 gene can also cause Meckel syndrome-2 (MKS2). 
1.7.3. JBTS#3: AHI1 
JBTS#3 is caused by homozygous or compound heterozygous mutations in AHI1 on 
chromosome 6q23.3 (Dixon-Salazar et al., 2004). Ahi1 is found at the mother 
centriole and the basal body of the primary cilia in mice (Hsiao et al., 2009). AHI1 is 
required for ciliogenesis and proper vesicular membrane trafficking. JBTS3 patients 
often presents with the core neurological manifestation as well as retinal dystrophy 
with no renal or hepatic involvement (Valente et al., 2006a). However, in a report by 
Utsch et al. (2006), findings indicate that AHI1 mutation can cause JBTS with renal 
manifestation.   
1.7.4. JBTS#4: NPHP1 
JBTS#4 is caused by homozygous or compound heterozygous mutations in NPHP1 
on chromosome 2q13, NPHP1 encodes nephrocytsin-1  (Parisi et al., 2004). Nphp1 
localized to the ciliary transition zone and functioned at an early stage of ciliogenesis 
in C. elegans (Williams et al., 2011). Mutation in NPHP1 can give rise to JBTS with 
retinal and renal involvement, as well as Senior-Loken syndrome-1 and juvenile 
nephronophthisis-1 (Sang et al., 2011).  
1.7.5. JBTS#5: CEP290 
JBTS#5 is caused by homozygous or compound heterozygous mutations in CEP290 
encoding the centrosomal protein CEP290 on chromosome 12q21(Valente et al., 
2006b).  CEP290 found to be involved in cilia assembly and ciliary protein trafficking. 
Mutation of CEP290 account for 50% of genetically diagnosed JBTS cases. CEP290 
mutations can give rise to JBTS5 where patients develop neurological manifestation 
accompanied with retinal disease and renal involvement or Senior-Loken syndrome 
(SLNS6) (Sayer et al., 2006). Later reports showed evidence of CEP290 mutation 
causing Leber congenital amaurosis LCA (den Hollander et al., 2006), MKS4  (Baala 
et al., 2007a) and Bardet-Biedl syndrome (BBS14) (Leitch et al., 2008). 
1.7.6. JBTS#6: TMEM67 
JBTS#6 is caused by homozygous or compound heterozygous mutations in 
TMEM67 on chromosome 8q22 (Baala et al., 2007b). It encodes the transmembrane 
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protein-67 (TMEM67) or Meckelin.  TMEM67 is localised to the primary cilia and take 
roles in ciliogenesis, centriole migration and renal tubulogenesis (Dawe et al., 2006). 
JBTS6 patients often present with renal disease and have a high tendency to 
develop liver fibrosis. TMEM67 truncating mutation was first found to cause MKS3 
(Smith et al., 2006). When the brain imaging lacks the presence of MTS in cases of 
TMEM67 mutation, NPHP11 is considered the diagnosis (Otto et al., 2009).  
1.7.7. JBTS#7: RPGRIP1L 
BTS#7 is caused by homozygous or compound heterozygous mutation in 
RPGRIP1L on chromosome 16q12. Found to be localised to the basal body and the 
centrosome of the primary cilia in different tissue, facilitating the vesicular docking of 
ciliary proteins at the transition zone (Delous et al., 2007). JBTS7 patients presents 
with the core neurological features, polydactyly, scoliosis and renal disease (Arts et 
al., 2007, Brancati et al., 2008). Mutation in RPGRIP1L may cause COACH (Doherty 
et al., 2010). 
1.7.8. JBTS#8: ARL13B 
JBTS#8 is caused by homozygous or compound heterozygous mutation in ARL13B 
on chromosome 3q11 (Cantagrel et al., 2008). It encodes member of the ADP-
ribosylation factor-like (ARL) family of small GTPases of the RAS superfamily 
(ARL13B). ARL13B exclusively localised to ciliary axoneme and takes a role in Sonic 
Hedgehog (SHH) signalling (Larkins et al., 2011) and cilia formation by targeting 
INPP5E to the cilia (Humbert et al., 2012). JBTS8 patients exhibit the classic 
features with or without retinopathy.  
1.7.9. JBTS#9: CC2D2A 
JBTS#9 is caused by homozygous or compound heterozygous mutation in CC2D2A 
on chromosome 4p15. It encodes coiled-coil and C2 domains-containing protein 2A 
(CC2D2A). CC2D2A is localised in basal body of primary cilia, regulating cilia 
directed cargo vesicle docking at the transition zone.  JBTS9 patients can develop 
retinopathy (Noor et al., 2008) , renal disease and hepatic fibrosis (Gorden et al., 
2008, Doherty et al., 2010).  
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1.7.10. JBTS#10: OFD1 
JBTS#10 is caused by mutation in the OFD1 gene on Xp22.2, giving rise to X-linked 
recessive inheritance JBTS (Coene et al., 2009). Mutation in OFD1 causing ciliary 
dysfunction and JBTS10 phenotype is associated with retinopathy and polydactyly or 
without (Field et al., 2012).  
1.7.11. JBTS#11: TTC21B 
JBTS#11 is caused by homozygous or compound heterozygous mutation in TTC21B 
on chromosome 2q24 (Davis et al., 2011). TTC21B encodes the retrograde 
intraflagellar transport (IFT) protein IFT139 which has been shown to localise to the 
cilia and regulate SHH signalling in primary cilia (Tran et al., 2014). Mutation in 
TTC21B can cause nephronophthisis-12 (NPHP12).  
1.7.12. JBTS12: KIF7 
JBTS#12 is caused by homozygous mutation in KIF7 on chromosome 15q26.1 
(Dafinger et al., 2011). Mutation in KIF7 associated with defective ciliogenesis and 
centrosome duplication resulting in SHH pathway disruption. Patients with JBTS12 
exhibit classic JBTS with dysmorphism and polydactyly. Mutation in KIF7 were first 
reported to cause acrocallosal syndrome (ACLS), an autosomal recessive mental 
retardation with absence of corpus callosum, dysmorphism, hallux duplication and 
polydactyly (Putoux et al., 2011).  
1.7.13. JBTS#13: TCTN1 
JBTS#13 is caused by homozygous or compound heterozygous mutation in TCTN1 
on chromosome 12q24 (Garcia-Gonzalo et al., 2011). Tctn1 localized to the 
transition zone between the ciliary axoneme and the basal body and plays major role 
in SHH signalling activation (Reiter and Skarnes, 2006) and ciliogenesis. Patients 
with TCTN1 mutation acquired no renal or hepatic disease (Alazami et al., 2012).   
1.7.14. JBTS#14: TMEM237 
JBTS#14 is caused by homozygous or compound heterozygous mutation in 
TMEM237 on chromosome 2q33. It encodes tetraspan transmembrane protein 
TMEM237 that interacts with other JBTS causing proteins at transition zone (Huang 
et al., 2011). The neuro-development features of JBTS14 was accompanied with 
polydactyly and renal cysts.    
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1.7.15. JBTS#15: CEP41 
JBTS#15 is caused by homozygous or compound heterozygous mutations in CEP41 
on chromosome 7q32 (Lee et al., 2012a). CEP41 encodes the centrosomal protein-
41 (CEP41) required for ciliary glutamylation regulating ciliary axonemal structure. In 
a small cohort of 8 patients with different CEP41 mutation gave rise to JBTS15 with 
core neurological symptoms, polydactyly and colobomas. 2 out of 8 patients had 
retinopathy, 1 patient with unilateral renal disease and another with hepatic 
manifestations. Digenic inheritance has been reported with other JBTS causing 
genes: KIF7 and CC2D2A.  
1.7.16. JBTS#16: TMEM138 
JBTS#16 can be caused by homozygous or compound heterozygous mutations in 
TMEM138 on chromosome 11q12 (Lee et al., 2012b). It encodes transmembrane 
protein TMEM138 that is localised to the base of the cilia and regulates vesicular 
trafficking. TMEM138 mutations affect ciliogenesis and manifest in JBTS with retinal 
and renal involvement.  
1.7.17. JBTS#17: C5orf42 
JBTS#17 is caused by compound heterozygous mutation in C5orf42 on 
chromosome 5p13 (Srour et al., 2012b). The neurological manifestations of 
JBTS#17 were associated with polydactyly with no evidence of with retinal, renal or 
hepatic disease (Bachmann-Gagescu et al., 2015). Mutation in C5orf42 were first 
identified to cause OFD VI.  
1.7.18. JBTS#18: TCTN3 
JBTS#18 can be caused by homozygous or compound heterozygous mutations in 
TCTN3 on chromosome 10q24, causing disruption of SHH signalling pathway 
(Thomas et al., 2012). In addition to core neurological manifestation of JBTS, patient 
with TCTN3 mutation had severe scoliosis. Mutation in TCTN3 were also found to 
cause OFD IV.  
1.7.19. JBTS#19: ZNF423 
JBTS#19 can be caused by homozygous and single heterozygous mutations in 
ZNF423 on chromosome 16q12.1. The single heterozygous alleles suggesting a 
dominant negative effect (Chaki et al., 2012). Mutations resulted in phenotypic 
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variability of JBTS. ZNF423 is a nuclear and centrosomal protein found to directly 
interact with another JBTS causing gene CEP290. 
1.7.20. JBTS#20: TMEM231 
JBTS#20 is caused by homozygous and compound heterozygous mutations in 
TMEM231 on chromosome 16q23.1 (Srour et al., 2012a). Mutations resulted in 
phenotypic variability of JBTS associated organ involvement, polydactyly, 
retinopathy and renal cysts were reported in different patients.  
1.7.21. JBTS#21: CSPP1 
JBTS#21 is caused by homozygous or compound heterozygous mutation in CSPP1 
on chromosome 8q13.1-q13.2 (Akizu et al., 2014). Mutation in CSPP1 affect 
ciliogenesis and may alter SHH signalling pathway, resulting in a wide spectrum of 
severity of JBTS (Shaheen et al., 2014, Tuz et al., 2014).   
1.7.22. JBTS#22: PDE6D  
JBTS#22 is caused by homozygous mutation in PDE6D on chromosome 2q37.1 
(Thomas et al., 2014). It encodes a basal body protein PDE6D which is essential for 
INPP5E ciliary trafficking through a functional network of many ciliary proteins 
(Humbert et al., 2012). Patients with JBTS22 commonly have polydactyly and 
develop retinal and renal manifestations.    
1.7.23. JBTS#23: KIAA0586 
JBTS#23 is caused by homozygous or compound heterozygous mutations in 
KIAA0586 on chromosome 14q23.1(Bachmann-Gagescu et al., 2015). Mutation of 
Talpid3, KIAA0586 orthologue in mice and chicken, is known to affect ciliogenesis 
and SHH signalling (Roosing et al., 2015). Mutation of KIAA0586 give rise to 
classical JBTS without retinal, renal or hepatic involvement.  
1.7.24. JBTS#24: TCTN2 
JBTS#24 is caused by homozygous mutation in TCTN2 on chromosome 12q24.31 
(Huppke et al., 2015, Sang et al., 2011). It encodes TCTN2 that affects ciliogenesis 
in a tissue specific manner by interacting with other ciliary proteins at the transition 
zone (Garcia-Gonzalo et al., 2011).  Patients with JBTS24 presented with 
  
23 
 
polydactyly and encephalocele, no evidence of retinal, renal or hepatic involvement. 
Mutation in TCTN2 can cause MKS8.  
1.7.25. JBTS#25: CEP104 
JBTS#25 is caused by homozygous or compound heterozygous mutation in CEP104 
on chromosome 1p36.32 (Srour et al., 2015). Loss of function mutation of CEP104 
can disrupt ciliogenesis by inhibiting cilia assembly (Tammana et al., 2013). No 
retinal, renal or hepatic disease were reported in JBTS#25 patients.  
1.7.26. JBTS#26: KIAA0556 
JBTS#26 is caused by homozygous mutation in KIAA0556 on chromosome 16p12.1. 
It encodes KIAA0556 protein localised at the basal body (Sanders et al., 2015). 
JBTS#26 patients exhibit milder form of JBTS with midline facial defect and rare 
association of growth hormone deficiency (Roosing et al., 2016b). 
1.7.27. JBTS#27: B9D1 
JBTS#27 is caused by homozygous or compound heterozygous mutation in B9D1 
on chromosome 17p11.2 (Romani et al., 2014). It encodes the B9 domain-containing 
protein 1 B9D1 localised at the basal body and function within the transition zone 
proteins complex (Dowdle et al., 2011). Mutations in B9D1 can cause mild form of 
JBTS with no extra neural manifestation or lethal form of MKS (MKS8).  
1.7.28. JBTS#28: MKS1 
JBTS#28 is caused by homozygous or compound heterozygous mutation in MKS1 
on chromosome 17q22 (Romani et al., 2014). MKS1 mutation gave rise to pure 
JBTS in two unrelated patients. Mks1 is required for ciliogenesis and renal tubule 
formation (Dawe et al., 2006). Mutations in MKS1 were first found to cause the lethal 
Meckel syndrome 1 (Kyttälä et al., 2006) as well as Bardet-Biedl syndrome 13 
(Leitch et al., 2008). 
1.7.29. JBTS#29: TMEM107 
JBTS#29 is caused by compound heterozygous mutations in TMEM107 on 
chromosome 17p13.1 (Lambacher et al., 2016). Mutation in TMEM107 can impair 
ciliogenesis and cause Meckel syndrome 13 (Shaheen et al., 2015).  
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1.7.30. JBTS#30: ARMC9 
JBTS#30 is caused by homozygous or compound heterozygous mutation in ARMC9 
on chromosome 2q37.1 (Van De Weghe et al., 2017). Patients with JBTS#30 
develop typical neurological features of JBTS with polydactyly and retinopathy and 
lack the renal or the hepatic involvement. 
1.7.31. JBTS#31: CEP120 
JBTS#31 is caused by homozygous or compound heterozygous mutation in CEP120 
on chromosome 5q23.2 (Roosing et al., 2016a).  Mutations in CEP120 can present 
with pure neurological JBTS symptoms without extra organ involvement as well as 
complex ciliopathy phenotype. 
1.7.32. JBTS#32: SUFU 
JBTS#32 is caused by homozygous mutation in SUFU on chromosome 10q24.32(De 
Mori et al., 2017). It encodes Suppressor of Fused (SUFU) a main negative regulator 
SHH signalling pathway. Patients with JBTS#32 exhibit polydactyly and cranio-facial 
dysmorphism.  
1.7.33. JBTS#33: PIBF1 
JBTS#33 is caused by homozygous or compound heterozygous mutation in PIBF1 
on chromosome 13q21 (Wheway et al., 2015). It encodes progesterone-induced 
blocking factor-1 (PIBF1). Patients can present with JBTS classical symptoms with 
polydactyly, retinal, renal or hepatic involvement.  
1.7.34. JBTS#34: B9D2 
JBTS#34 is caused by homozygous or compound heterozygous mutation in B9D2 
on chromosome 19q13.2 (Bachmann-Gagescu et al., 2015). Skeletal abnormalities 
and facial deformities were reported with no renal or hepatic involvement. B9D2 also 
known to cause MKS10 (Dowdle et al., 2011).  
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1.8. Phenotypic / genotypic overlap in Joubert syndrome 
As mentioned previously, JBTS have a noticeable genetic heterogeneity as well as 
phenotypic heterogeneity, that is biallelic or single allele mutations in many different 
genes cause the same disorder but with wide spectrum of severity and rang of other 
organs involvement. Some of the phenotypic association in JBTS are well developed 
and recognized and led to further classification of JBTS into clinical subgroups, 
which can guide in disease management in the absence of molecular genetic 
diagnosis. However, Molecular genetic diagnosis is important for family planning 
counselling, prognostic counselling and management of extra neural manifestations. 
Due to the broad heterogeneity in the clinical presentation and the genetic cause of 
JBTS, the preferred molecular genetic testing approach starts with multiple gene 
panel then followed by whole exome sequencing if the diagnosis not established 
(Vilboux et al., 2017). 
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Figure 1.3 Genotype-phenotype correlation in Joubert Syndrome 
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1.9. The primary cilia 
The primary cilium is a hair-like structure protruding from the cell surface in almost 
every cell type and is a highly conserved specialised organelle of the eukaryotic cell. 
The primary cilium consists of axoneme, the core of the cilium formed by a circular 
array of 9 microtubules doublets extending from the mother centriole named the 
basal body and a transition zone. Cilia assembly is thought to be linked to the cell 
cycle and happens to occur in consecutive steps. Ciliogenesis starts with the 
differentiation of mother centriole to the basal body, then the generation of the 
transition zone, finally the apical migration of axoneme to cell surface (Ishikawa and 
Marshall, 2011). Even though the ciliary membrane represents a continuation of the 
plasma membrane, the ciliary composition differs from the rest of the cell 
composition. Moreover, primary cilia lack the presence of ribosomes which restricts 
the protein synthesis within the cilium, which explains the presence of a highly 
specialised protein diffusion barrier at the transition zone that controls the trafficking 
of proteins in and out of the cilium. (Satir et al., 2010). An intraflagellar transport 
(IFT) machinery carries the proteins along the axoneme in two separate systems. A 
kinesin II-based system up toward the cilium tip and a dynein- based sysetem down 
toward the cilium base termed anterograde and retrograde IFT, respectively 
(Madhivanan and Aguilar, 2014). The IFT is essentially required for the assembly, 
elongation and the maintenance of the primary cilia. 
The highly-specialised structure of the primary cilia allows it to function as cell 
antenna, sensing, transducing and responding to various stimuli from and to the 
surrounding environment. Those various stimuli are received via specific ciliary 
receptors found along the ciliary membrane, including mechanoreceptors, 
thermoreceptors, photoreceptors, osmoreceptors, olfactory receptors and hormones 
receptors. The cells response to these extracellular stimuli regulates proliferation, 
differentiation, polarity, growth and morphology. The primary cilia play vital role in 
regulating signalling pathways crucial for normal embryonic development like sonic 
hedgehog (SHH), Wnt and Notch pathways (Hildebrandt et al., 2011a, Goetz and 
Anderson, 2010).  
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Figure 1.4 Schematic representation of the structure of the primary cilium and 
its protein complexes 
Figure taken from (Romani et al., 2013) 
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1.10. Maintaining the ciliary protein composition  
It's the cilia distinct protein composition that promotes its signalling function. The 
primary cilia maintain its unique protein compositing through controlling protein 
access to and from the cilium as well as protein to protein interaction within the 
cilium. Proteins enter the cilia are either integral membrane proteins, small soluble 
proteins, large soluble proteins or membrane associated protein. Ciliary proteins gain 
their entry to the cilium by lateral transport from the plasma membrane and vesicular 
trafficking of ciliary proteins from Golgi at the base of the cilia (Nachury et al., 2010).   
As mentioned above, primary cilium is an isolated domain, while the ciliary 
membrane separates the cilia projection into the extracellular compartment, it's the 
presence of the barrier at the base of the cilia that's draw its cellular boundaries. The 
barrier components are the periciliary membrane, transition fibres, ciliary necklace 
and ciliary pockets (Madhivanan and Aguilar, 2014). The periciliary membrane arises 
where the basal body distal appendages are attached.  The transition fibres (arising 
from distal appendages) form a propeller like structure with nine sheets connecting 
the centriole directly to plasma membrane, allowing only too small vesicles to pass 
through. Distal to the transition fibres lies a septin ring believed to separate the 
periciliary compartment from the ciliary compartment and function as diffusion barrier 
at the base of the cilium (Hu et al., 2010). More distal is the transition zone where the 
ciliary necklace connects the axonem to the ciliary membrane, consisting of protein 
complexes forming ‘Y-links’ structures (Garcia-Gonzalo and Reiter, 2017). Ciliary 
proteins complex at the transition zone function as smart gate officers validating the 
access of ciliary cargo proteins preloaded at the transition fibres allowing their 
trafficking to the ciliary axonem.  
Specialised short signal sequence were found to play essential role in directing and 
trafficking ciliary proteins to the cilia, known as Ciliary targeting signals (CTSs) 
(Malicki and Avidor-Reiss, 2014). CTSs were often found to localise at the protein C-
terminus, less likely at the N-terminus or rarely at the intracellular loop. Many CTSs 
have been reported with different localisation and different role in ciliary targeting 
from one protein to another. A good example is the QVSAPA sequence, first being 
reported to mediate the interaction of Rhodopsin with its carrier Arf4 to be 
transported from Golgi in cases of retinitis pigmentosa caused by mutation in RHO 
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the gene encoding Rhodopsin (Deretic, 2006). In contrast, disruption of the same 
QVSAPA sequence in INPP5E has no effect on its ciliary localisation (Humbert et al., 
2012). Small size soluble protein ciliary trafficking is mediated by diffusion and 
retention rather than active transport machinery, on the other hand, large soluble 
proteins require CTSs as well as GTP/GDP gradient to facilitate their entry at the 
base of the cilia (Kee et al., 2012). 
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Figure 1.5 Ciliary membrane protein trafficking  
(A) Structure of cilia base diffusion barrier “the transition zone” consisting of ciliary 
necklace, Y-links and transition fibres. 
(B) Post Golgi vesicles delivering membrane protein to the cilia by fusing with 
ciliary membrane.  
(C) Post Golgi vesicles are delivered to plasma membrane then cross the 
diffusion barrier to reach ciliary membrane   
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1.11. Ciliary trafficking of post-translational lipid-modified proteins 
Myristolation and prenylation are post-translational lipid-modification of some of the 
membrane associated proteins to increase their membrane hydrophopicity. 
Myristolation is the addition of hydrophobic myristoyl group to protein N-terminus, 
while prenylation is the addition of hydrophobic prenyl group to protein C-terminus. 
Some of ciliary proteins are lipid-modified like INPP5E and PDE6. Lipid-modified 
ciliary proteins require solubilising factors to promote their ciliary trafficking known as 
Guanosine nucleotide Dissociation Inhibitor (GDI) like solubilising factors (GSFs) 
including PDE6D, UNC119a and UNC119b proteins (Wright et al., 2011). Upon their 
entrance to the cilia, GSFs bind to their releasing factors releasing the ciliary cargo 
to the ciliary membrane. ARL2 and ARL3 are known releasing factors, small G-
proteins belong to the ADP ribosylation factor-like (Arf-like) subfamily (Ismail et al., 
2011).  ARL3 localises to the cilia whereas ARL2 function at the periciliary 
compartment. Releasing factors activity is GTP dependent, regulated by guanine 
exchange factor (GEF) promoting the binding of the release factor to the GSF and 
inducing a conformational shift releasing the ciliary cargo.  Also, regulated by 
GTPase-activating proteins (GAP) that inactivate the release factor by switching it to 
the GDP-bound state. ARL3 has major role in cytokinesis and cilia signalling (Zhou 
et al., 2006). A heterozygous ARL3 human mutation has been previously reported in 
a patient with retinal dystrophy and biallelic ARL3 loss of function in mice leads to 
typical ciliopathy phenotype with severe manifestations (Schrick et al., 2006). ARL3 
is regulated by its GEF ARL13B, cilia-specific protein when mutated in human gives 
rise to JBTS with retinopathy (Gotthardt et al., 2015). ARL3 also regulated by its 
GAP RP2, a pre-ciliary protein when mutated in human leads to X-linked non 
syndromic retinitis pigmentosa (Veltel et al., 2008). 
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1.12. Patient-derived cells to model ciliopathies  
The presence of primary cilia is a characteristic of various tissues and cell types as 
well as cultured cell lines. The early identification of primary cilia structure and 
frequency was done by electron microscopy, which is labour extensive and time-
consuming process for research and experiments (Smith et al., 1969, Rieder et al., 
1985). Later came the implication of immunostaining techniques experiments with 
antibody against microtubules (Ho and Tucker, 1989, Kilmartin et al., 1982).  Alieva 
et al. (1999) proposed an experimental model using intensive immunofluorescence 
antibodies against primary cilia in different tissue cultures, to study cilia frequency 
and correlation to cell cycle using light microscopy.  
Many investigators used patients derived cells to study the disease pathogenesis, 
especially for diseases like ciliopathies.  Fibroblasts make the skin basal layer 
(dermis) contain primary cilia, which can be derived and cultured from skin biopsies 
(Wilson and McWhorter, 1963). In vitro, the monolayer fibroblast cell culture can 
reach confluency with percentage of ciliation up to 90% (Wheatley, 1995). The use of 
electron microscopy (Figure 1.6) and immunofluorescent staining microscopy 
(Figure 1.7) of patients derived fibroblasts cell culture had been widely reported 
using specific immunofluorescent antibodies against basal body, axoneme, cilia 
membrane and ciliary cargo proteins (Novarino et al., 2011). Such techniques allow 
good cilia visualisation and assessment of its structure and function. 
A good example of human derived-cells to study primary cilia are the renal tubular 
epithelial cells. However, obtaining human renal tissue is a difficult process requiring 
invasive procedure such as renal biopsy. Renal biopsies can be traumatic and carry 
significant morbidity and a small, but real, risk of mortality (Corapi et al., 2012). 
Human urine derived renal epithelial cell (HUREC) culture is a non-invasive way of 
isolating human renal tubular epithelial cells from both adults and children and 
serving as an excellent model to study ciliopathies (Srivastava et al., 2017, 
Ajzenberg et al., 2015) Figure 1.8.  
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Figure 1.6 Scanning electron microscopy (SEM) images of patients-derived 
fibroblasts with ciliopathies.  
Fibroblasts from affected individuals with ciliopathies seen under SEM showing:  
A. Long cilia in CEP290 patient fibroblasts causing JBTS  phenotype  
B. Dilatation of ciliary membrane phenotype in OFD patient fibroblasts  
C. Normal appearances of primary cilia in ARL3  patient fibroblasts causing 
JBTS phenotype 
D. Wild type (WT) (Scale bar 2 µm).  
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Figure 1.7 Fibroblast cilia derived from patient with CEP290 mutation causing 
Joubert syndrome 
Immunofluorescence staining using anti-alpha-acetylated tubulin (red) to identify 
axoneme and anti-ARL13B (green) to identify ciliary membrane in healthy carrier (A) 
and JBTS (B) cells in low power and zoomed. Scale bar 5 µm. 
 
 
 
 
A B
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Figure 1.8 Human urine renal epithelial cell (HUREC) cilia derived from a 
patient with CEP290 mutations causing JBTS phenotype  
Immunofluorescence staining using anti-alpha-acetylated tubulin (red) to identify 
axoneme and anti-ARL13B (green) to identify ciliary membrane in wild type (A) and 
JBTS (B) cells (Scale bar 5 µm). Image taken from (Srivastava et al., 2017) 
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1.13.  Aims of project 
According to the literature ciliopathies are caused by mutations in more than 50 
genes and up to date genetic causes of JBTS are unknown in >50% of the clinically 
diagnosed cases. Via the renal family genetics clinic, we aim to: 
1. Define clinical phenotypes of cohorts of patients with renal ciliopathies. 
2. Explore molecular genetic diagnosis in “unsolved” ciliopathy patients with 
Joubert syndrome in order to identify novel genetic causes; undertake whole 
exome sequencing and examine candidate gene variants with in silico tools 
and explore gene expression profiles. 
3. Undertake cell biological studies to explore mechanism of action of novel 
JBTS causing gene. 
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Chapter 2 Materials and Methods 
2.1. Consent and ethical approvals 
All patients and their relatives consented to this study. Ethical approval was obtained 
from the National Research Ethics Service (NRES) Committee Northern and 
Yorkshire (09/H0903/36) for urine cell studies and NRES Committee North East – 
Newcastle and North Tyneside 1 (08/H0906/28+5) for DNA and biobanked 
fibroblasts. Following informed and written consent, blood samples were obtained 
from affected patients and their relatives and healthy gender and age-matched 
controls. Skin fibroblasts were obtained from patients and their relatives following 
informed written consent and stored in Newcastle MRC Centre Biobank for 
Neuromuscular and Rare Diseases.  
2.2. Clinical review of patients 
Patients and family members were seen within the context of a regional family renal 
genetics clinic, run by Professor Sayer at Newcastle Hospitals NHS Foundation 
Trust. This clinic allows pedigrees to be drawn, clinical history and examination to be 
performed and molecular genetic testing to be discussed. Families were invited to 
join and consent to research studies following these discussions. 
2.3. DNA sampling and genetic studies 
Genomic DNA was extracted from venous blood from affected siblings, unaffected 
siblings and their unaffected parents and relatives using a DNA extraction robot 
based at the Northern Genetics Service, Newcastle.  
Genomic DNA (2µg) from two affected siblings and their parents was subjected to 
whole exome paired-end sequencing analysis with 100× coverage by generating 51 
Mb Sure Select V4 libraries (Agilent Technologies, USA). The sequence reads were 
run on a HiSeq2500 platform (Illumina, San Diego, CA, USA). Bioinformatic pipelines 
provided by GATC generated vcf files. Ingenuity Variant Analysis web-based 
application and HomozygosityMapper (http://www.homozygositymapper.org/) was 
used for data analysis of vcf files. The variants of interest were further tested for 
likely pathogenicity using in silico prediction tools.  
In silico prediction tools were used are PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph/), Provean (http://provean.jcvi.org/index.php), 
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and MutationTaster (http://www.mutationtaster.org/). PolyPhen-2 scores range from 
0 to 1, the higher the score the more damaging the amino-acid substitution. Provean 
scores range from 0 to 1. The amino-acid substitution is predicted damaging if the 
score is ≤ 0.05, and tolerated if the score is > 0.05. Allele frequency of novel 
sequence variants was determined using the Exome Aggregation Consortium 
(ExAC) database (http://exac.broadinstitute.org/) and the Genome Aggregation 
database (gnomAD) (http://gnomad.broadinstitute.org). Z score is used to quantify 
deviation from expectation; synonyms variants are centred at zero and significant 
shift to higher values constrain missense and nonsense mutations.  
The variants were confirmed using Sanger sequencing in all available family 
members to confirm segregation with disease status. 
Primers for ARL3 exon 5 were designed using online tool Primer 3 
(http://primer3.ut.ee/) 
ARL3 forward primer 5’-TCGGTTAGCTGTCATGTTGC-3’     Predicted DNA 
length  400 bp 
ARL3 reverse primer 5’-CTGGGAAGCGAAGGTTGC-3’ 
Primers were constructed by Integrated DNA Technologies, Inc.    
2.3.1. PCR Protocol  
PCR reactions used 50-100 ng of genomic DNA, 10 pmol of forward and reverse 
primers and Taq PCR Master Mix (Qiagen, cat No. 201445)     
A typical 30 µl PCR reaction consisted of 1 µl of DNA, 1 µl of forward and reverse 
primers, 15 µl Master Mix and 12 µl water.  
Using a touchdown PCR, cycling conditions were as follow; 95°C for 10 min, 94°C 
for 20 s, 72°C for 20 s, 72°C for 1 min, 94°C for 20 s, 54°C for 20 s, 72°C for 1 min 
for 20 cycles, 72°C for 10 min and a final hold of 4°C to stabilise and prevent 
degradation of PCR product.  
2.3.2. Agarose Gel electrophoresis  
PCR amplification products were analysed using Agarose gel electrophoreses. 3 ml 
of 6X loading dye (Promega, G190A) was added to 5 ml of PCR products to track 
the migration during electrophoresis, then loaded on 2% agarose gel (NBS biological 
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Agarose Low EEO cat # NBS-AG500) with 1X TAE buffer. GelRedTM (Biotium, cat # 
41003) was added to the gel mixture prior casting to visualise the DNA fragments 
band.  5 ml 100bp DNA ladder (Promega, G2101) was loaded to determine the size 
of DNA product (400 bp). DNA bands were sufficiently separated after 30 minute at 
100V. 
2.3.3. DNA purification 
DNA purified from PCR products by centrifugation using Wizard ® SV gel and PCR 
clean up system (Promega, REF A9281). An equal volume of Membrane binding 
solution was added to the PCR amplifications. Then the dissolved mixtures were 
transferred to collection tubes with SV Mini-columns and centrifuged at 16,000x g for 
1 min after incubation period of 1 minute at room temperature. Followed by washing 
steps, 700 µl of Membrane wash Solution added then then centrifuge at same speed 
for 1 min to remove solution. Washing repeated but with 400 µl Membrane wash 
solution and 5 min centrifugation. Recentrifugation of the last wash for 3 minutes with 
microcentifuge lid open to allow evaporation of residual ethanol. Last step, DNA 
elution was prepared by transferring SV Mini-columns to 1.5 ml centrifuge tube, 
adding 50 µl of Nuclease-free water and incubation at room temperature for 1 min. 
centrifuge at same speed for 1 minute the discard the mini-column and store DNA at 
4°C.  
DNA purified from PCR products were sent with forward primer for Sanger 
sequencing to GATC Biotech (Cologne, Germany).    
Sequenced data were downloaded as ab1, seq or fas file and analysed using 
software including MutationSurveyor and Chromas. 
2.4. Fibroblasts 2D cell culture 
Skin biopsies taken from patients and controls unaffected carrier parents and 
unaffected wild type sibling by Dr David Steel, Sunderland Eye Infirmary and stored 
in Newcastle Biobank. Specimens were transported in a sterile tube containing 6 ml 
of Ham’s F-10-complete Medium at 4°C before processing.    
Patients and control fibroblasts were isolated from skin biopsies, grown at 33°C in 
T25 cell culture flasks with Fibroblast growth medium. After reaching confluency of 
80-90%, cells were detached using 3ml of trypsin and re-suspended with growth 
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media. After centrifugation for 5 min at 1200 rpm, cells were re-suspended in growth 
media and splitting in 1:4.     
2.4.1. Fibroblast growth medium 
DMED 1X (Thermo Fisher, 41966-29), 10% foetal bovine serum (Thermo Fisher, cat 
# 10500056) and 1% Penicillin /Streptomycin (Thermo Fisher, 15070-063). 
For ciliogenesis and ciliary protein signal intensity experiments, cells were seeded on 
coverslips and grown to 70-90% confluency then starved for 48 h (in minus FBS 
medium) to induce ciliogenesis.  
For the SAG experiment, cells were seeded on coverslips and grown to 70-90% 
confluency then cells were treated with 100 nM SAG (Tocris cat# 4366) after 24 h of 
starvation. Next, cells were incubated for another 24 h in starvation medium. 
Cells on coverslips were fixed with 100% ice cold methanol for 15 min, washed three 
times with Phosphate-buffered saline (PBS).  
2.5. Immunofluorescence staining  
Coverslips were blocked for 30 min to 1 h in PBS with 10% bovine serum albumin. 
For indirect immunostaining of primary cilia, primary antibodies diluted in blocking 
solution rabbit anti-INPP5E 1:100 (Proteintech 177197-1-AP), rabbit anti-GLI3 1:200 
(Abcam ab69838) and mouse anti-PERICENTRIN 1:1000 (Abcam ab28144) and 
incubated in room temperature for 1 hr or in 4 °C overnight NPHP3 1:100  
(Proteintech 22026-1-AP). Followed by three washes with PBS 15 min each. Cells 
were incubated at room temperature for 1 h with Alexa Fluor conjugated secondary 
antibodies diluted in blocking solution 1:400 donkey anti-rabbit Alexa Fluor 488 
(Thermo Fisher Scientific); goat anti-mouse Alexa Fluor 647 (Thermo Fisher 
Scientific) followed by three washes 15 min each.  
For direct immunostaining of primary cilia, Zenon Tricolor Rabbit IgG Labelling Kit 
(Thermo Fisher, Z-25360) was used. Primary antibody ARL13B 1:400 (Proteintech, 
17711-1AP) diluted in PBS was mixed with 5 µl of labelling mix, incubated at room 
temperature for 5 min. 5 µl of blocking mix was added, followed by a further 
incubation for 5 min. Cells were incubated overnight in 4°C in labelled antibody 
solution followed by three washes in PBS-Tween 20% 15 min each. Cells were re-
fixed in 4% PFA for 15 min at room temperature then washed 3 times with PBS. 
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Coverslips were mounted on slides using mounting medium with DAPI Vectashield 
(Vector Laboratories Ltd, H-1200).   
2.6. Confocal microscopy 
Images were obtained with confocal microscopy (Nikon A1), with an optical 
magnification of 60X and additional digital zooming of desired filed to gain better 
image quality. Z-stacks were created using the same laser intensity as well as 
camera settings. Images were captured and exported as ND2 file. 
Image analysis obtained using Fiji (ImageJ) software. 
2.6.1. Cilia length and ciliation rate  
For experiment quantifying the percentage of ciliogenesis, 4-5 60X fields were 
analysed then the average was calculated. For each field the percentage of ciliated 
cells labelled with ARL13B was scored as a proportion of total nuclei labelled with 
DAPI. The segmented line tool was used to measure cilia length from base of 
axoneme (PERICENTRIN) to cilia tip on a maximum intensity projection of a z-stack.   
2.6.2. Ciliary antibody signal intensity  
For antibody signal intensity quantification experiments, 4-5 60x fields were 
analysed. On a sum slices intensity projection of a z-stack, freehand tool was used 
to mark cilia borders using ARL13B signal, the region of interest (ROI) constructed to 
measure the mean signal intensity of ciliary antibody staining (e.g. INPP5E, NPHP3 
or GLI3). Then ROI was duplicated and dragged to nearby area to correct for local 
background intensity by simple subtraction.  
2.7. Electron microscopy methods 
Processing and imaging technique for scanning electron microscopy (SEM) were 
provided by Dr. Kathryn White, EM Research Serveries, Newcastle University.   
Patients and control fibroblasts cells were seeded on transwell filters and incubated 
for 24 h in fibroblast growth media at 37°C. Then were starved for 48 h to induce 
ciliogenesis.  
Samples were fixed in 2% glutaraldehyde Sorenson’s phosphate buffer solution 
(provided by EM services, Newcastle University) and kept in 4°C overnight. Prior 
sending to EM services, samples were dehydrated in ethanol solutions (25%, 50%, 
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75% - 30 minutes each). Followed by 2X wash with 100% ethanol 1 h each.  A final 
dehydration with carbon dioxide in a Baltec Critical Point Dryer was used. Samples 
were then mounted on sticky carbon discs and coated with gold, 5-10 nm, using a 
Polaron SEM Coating Unit. Samples were examined using TESCAN VEGA LMU 
Scanning Electron Microscope and the images were collected with TESCAN 
supplied software.  
2.8. Human urine-derived renal epithelial cells culture (HURECs) 
Urine sample were collected from patients / controls (50-100 ml) in sterile containers, 
kept in 4°C while and processed within 4 h of collection. Samples were transferred to 
falcon tubes and centrifuged for 10 min at 400 rcf then the pallet was re-suspended 
in 10 ml of washing buffer. Further centrifugation of the suspension for 10 min at 200 
rcf. Later the pallet was re-suspended in 2 ml of primary media and plated in a single 
well of 12-well plate and incubated at 37°C and 5% CO2. For the next 96 h, 1 ml of 
primary media was added each day. On day 4, 4 ml of primary media were decanted 
and replaced with 1 ml of proliferation media. Every day, 1 ml of media was removed 
and 1 ml of fresh media was added. 
The epithelial cells begin to appear on day 5-14 and can be used for passaging or 
experiments after reaching 80- 90% confluence.  
2.8.1. Primary medium for HUREC culture  
Primary medium for HUREC has the following components – 5% Fetal Calf Serum, 
Penicillin/Streptomycin (140 U/ml+140 U/ml), Amphotericin B, Supplements of 
REGM Single quot kit, DMEM/High Glucose, Ham’s F12 Nutrient Mix.  
2.8.2. Proliferation Medium for HUREC culture  
Proliferation medium for Human Urine derived Epithelial Cell culture has the 
following components - Penicillin/Streptomycin (140 U/ml+140 U/ml), Amphotericin 
B, Supplements of REGM Single kit (Lonza, CC-3190), REBM medium from the 
REGM Bullet kit (Lonza, CC-4127).  
2.8.3. Washing Buffer for HUREC culture  
Washing Buffer is DPBS (Thermo-Fisher) supplemented with Penicillin/Streptomycin 
(140 U/ml+140 U/ml), Amphotericin B (1 µg/ml).  
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2.9.  siRNA ARL3 knockdown experiment  
HURECs (0.05 x 106) were transfected with 5 pmol Negative Control siRNA 
(AM4611, ThermoFisher) and siGENOME Human ARL3 siRNA- SMARTpool 
(DharmaconTM, M-011813-00-0005), using Lipofectamine RNAiMAX 
(ThermoFisher, 13778150) under manufacturer’s instructions.  
2.9.1. Whole cell RNA extraction  
HURECs were grown to confluency on 6-well plates and treated as described above. 
48 h after transfection, cells were rinsed with PBS to remove floating dead cells, 
media and transfection reagents. 200 µl of protein extraction buffer (4 M urea, 125 
mM Tris pH 6.8, 4% SDS, 10% glycerol, 5% β-mercaptoethanol and 0.02% 
bromophenol blue solution) was added and the cells were removed from the well 
using cell scrapper. Samples were aliquoted and stored at 20°C until required.   
RNA was extracted by spin technology using RNeasy® mini kit (QIAGEN) according 
to the manufacturer’s instructions, and quantified using a NanoDrop 2000 
Spectrophotometer (Thermo Fisher Scientific).  
2.9.2. Reverse Transcription  
Reverse transcription was required to produce cDNA from RNA using SuperScript 
III® Reverse Transcriptase (Invitrogen).  1 µg of RNA was reverse-transcribed using  
RT-PCR was required to confirm the knockdown of ARL3 gene at protein level.  
2.9.3. RT-PCR methods 
The resulting cDNA was diluted 10-fold in nuclease-free water. Real-time PCR was 
carried out in a 10 µl reaction volume containing the following: 0.5ul of each primer 
(10uM stock) with 0.5 µl water, 4 µl of cDNA and 5 µl of  PrimeTime® Gene 
Expression Master Mix (IDT). The PCR was run using a QuantStudio™ 7 Flex Real-
Time PCR System (Applied Biosystems) using the following settings: 95°C for 20 
seconds, followed by 40 cycles of 95°C for 1 second 60°C for 20 seconds. The 
PrimeTime® assays used were as follows: GAPDH (Hs.PT.39a.22214836), HPRT1 
(HsPT.58.20881146), and ARL3 (Hs.PT.56a.40668589) all structured by Integrated 
DNA Technologies, Inc.  
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2.10. Homology modelling 
Human ARL3 (UniProt accession code P36405) and ARL13B (UniProt accession 
code Q3SXY8) were modelled on the crystal structure of the Arl3-Arl13B complex 
from Chlamydomonas reinhardtii (PDB accession code 5DI3) using HHPred (REf1) 
and Modeller (REF2) software. Structures were visualised, and figures prepared 
using PyMOL (http://www.pymol.org/). 
2.11. Protein expression and purification 
Chlamydomonas reinhardtii and murine full-length ARL3, Chlamydomonas reinhardtii 
ARL13B 18-278, and human full-length UNC119A were expressed and purified as 
previously described (Ismail et al., 2012). Human ARL13B 18-278 was cloned into 
pET20b with an N-terminal 12×His-tag and purified using the same protocol as ARL3 
with the addition of 10% glycerol to the purification buffers and storing the protein in 
5% glycerol. p.Arg149His mutation in ARL3 and p.Glu86Arg mutation in ARL13B 
were introduced using the Q5 site directed mutagenesis kit (NEB). 
2.12. Guanine nucleotide exchange assay 
Murine ARL3 used for GST pull-downs was exchanged with the non-hydrolysable 
analogue of GTP, GppNHp. 300 µM ARL3 was incubated with 2 mM GppNHp and 
0.14 U/µL Alkaline Phosphatase (Roche) overnight at 15°C. Excess nucleotides 
were removed by size exclusion chromatography on a Superdex S200 Increase 
column (GE Healthcare). GppNHp-loaded ARL3 was quantified using HPLC analysis 
and C18 columns (UltiMate3000, Thermo Fisher Scientific). For the GEF assay, 
nucleotide exchange of murine and Chlamydomonas reinhardtii ARL3 proteins with 
mantGDP was carried out by incubating 100 µM ARL3 protein with 200 µM 
mantGDP for 2 h at room temperature in the presence of 50 mM EDTA. For 
nucleotide exchange to GppNHp on human and Chlamydomonas reinhardtii 
ARL13B, 100 µM ARL13B was incubated with 500 µM GppNHp and 50 mM EDTA, 
also for 2 h at room pressure. All reactions were carried out in 20 mM tris pH 7.5, 
150 mM NaCl, 5 mM MgCl2 and 2 mM DTT and were stopped by adding 100 mM 
MgCl2. Unbound nucleotides were removed by using a PD10 desalting column (GE 
Healthcare), and the proteins were concentrated using Amicon Ultra 0.5 mL units 
(Merck Millipore) with a molecular weight cut-off of 3 kDa. All reactions were carried 
out in 20 mM Tris pH 7.5, 150 mM NaCl, 5 mM MgCl2 and 2 mM DTT at room 
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temperature. Fluorescence polarisation was measured at an excitation of 366 nm 
and emission of 450 nm. 0.5 µM of CrARL3•mantGDP was measured for 100 s, after 
which 10 µM GppNHp was added and measured for an additional 100 s. Finally, 5 
µM of CrARL13B•GppNHp was added and changes in fluorescence polarisation 
were recorded for 300 s. The same was repeated for HsARL13B, but starting with 1 
µM of murine ARL3•mantGDP to which 400 µM GppNHp was added followed by 5 
µM HsARL13B. 
2.13. GST pull-downs 
30 µg of GST-tagged full-length UNC119A and 60 µg of GppNHp-loaded murine 
ARL3 WT and p.Arg149His were incubated in 20 mM Tris pH 7.5, 150 mM NaCl, 5 
mM MgCl2 and 2 mM DTT for 15 minutes at room temperature before adding to 
Glutathione sepharose 4 FF beads (GE Healthcare) and incubating for a further 20 
minutes. Beads were washed 5 times in reaction buffer before eluting with reaction 
buffer containing 20 mM Glutathione.   
  
47 
 
Chapter 3  Overview of Renal-Genetic Family Clinic 
3.1. Introduction and aim 
Inherited kidney disorders are classified under rare disorders, which affect a limited 
number of individuals defined as affecting <1 in 2000 people in Europe or < 200 000 
people in the USA (Schieppati et al., 2008). Rare kidney disorders include at least 
150 different diseases with an overall prevalence of about 60-80 cases per 100 000 
in Europe and the USA (Soliman, 2012).  
Inherited disorders have a well-recognised medical, psychosocial and economic 
burden on the affected families, as well as the health care provider. Inherited kidney 
disorders are known to cause chronic kidney disease progressing to end stage renal 
disease (ESRD) requiring dialysis or renal transplantation in both children and adult 
populations. The primary causes of chronic kidney disease in children differ from 
those in adults. In the UK, the causes of ESRD in children include congenital 
anomalies of the kidneys and urinary tract (CAKUT)  in ~ 35% of cases, congenital 
nephrotic syndrome in 10% and cystic kidney disease in 5% of cases (Karger and 
Paris, 2013). A report from the USA agreed with the causes of childhood ESRD with 
an increased prevalence of CAKUT of 49.1% (Smith et al., 2007). CAKUT is also 
responsible for a significant proportion of adult or late onset ESRD, whereas, 
autosomal dominant polycystic kidney disease (ADPKD) accounts for ~10% of adult 
ESRD in the UK (Julie Gilg, 2015). Mutations in genes encoding transcription factors 
essential for renal development and maintenance including WT1, PAX2 and HNF1B 
may lead to both renal tract malformation and renal syndromes with significant extra 
renal manifestations (Thomas et al., 2011). Mutations in the COL4 genes give rise to 
inherited collangenopathies such as Alport syndrome (a recognised cause of adult 
onset kidney disease) and familial haematuria syndromes (Gast et al., 2016). 
Early recognition and awareness of inherited kidney disorders are required by taking 
a detailed family history (McCloskey et al., 2016). Diagnosis and management of 
these forms of disease are extremely important. The diagnostic process of inherited 
disorders practiced by most clinical geneticists is long and exhausted, with clinical 
assessments followed by subsequent laboratory and genetic testing based on each 
previous test being negative. The combined practice of a multidisciplinary clinic and 
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the application of next-generation sequencing has facilitated a more streamlined 
identification of the genetic causes of inherited kidney diseases.  
We aim to describe a cohort of patients attending a multidisciplinary renal genetics 
family clinic in the north of England and the insights gained from this clinic 
experience.  
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3.2. Materials and Methods 
A multidisciplinary renal genetics family clinic was established in 2010 in the Renal 
Services Department of Freeman Hospital, Newcastle Upon Tyne Hospitals NHS 
Foundation Trust. The clinic aims to find precise molecular genetic diagnosis for 
patients with inherited renal disorders, guide management, provide genetic 
screening, and proper genetic counselling to the attending families. The clinic is 
hosted every three months where the patients and their families have the opportunity 
to meet with an adult nephrologist, paediatric nephrologist and a clinical geneticist 
simultaneously in the same clinic session and room. The clinic is a gateway to 
perform genetic testing, using targeted single gene screening and gene panels 
available by the UK Genetic Testing Network (UKGTN, https://ukgtn.nhs.uk/). A 
retrospective review of clinic cases and their molecular genetic diagnosis over a 5-
years period was performed. Patients’ data were reviewed from the hospital 
electronic records. Individual's age at referral, date of birth, sex, ethnicity, address 
and reasons for referral were extracted. The probands’ medical history and a three-
generation family pedigree/history were taken and the presence or the absence of a 
genetic diagnosis prior referral was noted. Outcomes includes genetic diagnosis 
following the clinic visit and specific management plans were reached when 
possible.   
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3.3. Results  
3.3.1. Newcastle family renal genetics clinic demographics 
 Between 2010 and 2015 a total of 244 individuals were seen in the clinic, 80 
probands and 164 family members; 50 affected relatives and 114 unaffected 
relatives. The number of relatives ranged from 1 to 7 family members in total and 
with a mean of ~3 members per referral. The age of probands at their first clinic 
review ranged between newborns to adults of 57 years of age. A fifth of probands 
were under 18 years old and the mean age at the time of referral was ~19-year-old. 
Probands were from white Europeans families with no know consanguinity, except 
six probands of Asian origin, two of whom were from consanguineous families.  
Referrals were from different NHS services; the clear majority were from paediatric 
nephrology services accounting for 56 of the 80 probands. The rest were from adult 
nephrology (14 cases), primary care (4 cases), clinical genetics (3 cases), surgery 
(2) and oncology (1 case) Figure 3.1. 
 
 
 
Figure 3.1 Origin of referral into Newcastle family renal genetics clinic 
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The renal family genetic clinic at Freeman Hospital in Newcastle upon Tyne was 
designed to be a tertiary referral centre serving not only local referrals but also 
attracting cases from the whole of the north of England. Individuals were referred 
from as far as Scarborough (99 miles) and Whitehaven (97 miles) Figure 3.2. 
 
Figure 3.2 Reach of Newcastle family renal genetics clinic 
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3.3.2. The clinic setting 
The probands and their relatives met the clinicians in a relaxed outpatient setting, 
initial investigations included blood pressure and urine sample to detect proteinuria 
and haematuria. Explaining the aim of clinic was crucial to reassure some of the 
individuals regarding their visit. Discussion, usually bidirectional, detailed medical 
history and extended family medical history were taken by physicians, on the other 
hand, family questions and concerns were answered. Following consent venous 
blood samples or mouth swabs were collected from probands and their relatives for 
DNA extraction and molecular genetic testing. Genetic testing was personalised for 
each case and varied between targeted gene test, panels, whole exome or whole 
genome sequencing as well as segregation studies in some cases. Renal imaging 
was requested when applicable and other specialist referrals were ordered when 
required to further investigate cases with extra renal manifestations.  
Generally, the reviewed individuals had an unknown or imprecise clinical genetic 
diagnosis and were referred to find a molecular genetic diagnosis and further 
investigations to clarify the clinical picture. This was the common reason for referral 
in 62 probands, whereas eighteen probands had a known genetic diagnosis in hand 
prior to referrals and were referred for genetic counselling, genetic screening for 
other family members and disease management with regards to their genetic results 
Table 3.1. The probands clinical features and reasons for referrals varied, yet most 
common reasons were for investigating suspecting familial haematuria in patients 
presented with proteinuria or investigating a possible diagnosis of inherited cystic 
kidney disease Figure 3.3. The remainder of the referrals were a mix of syndromic 
and isolated kidney diseases. A precise molecular genetic diagnosis successfully 
achieved following the clinic in 26 cases (42%) out of 62 cases referred without 
genetic diagnosis Table 3.2. Despite targeted genetic testing of candidate genes, 
some cases remained unsolved. This include nine probands and their relatives who 
have been recruited into further genetic projects the Newcastle pilot study of the 
Genomics England 100000 Genomes Project Figure 3.4. 
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Figure 3.3 Clinical features of the proband and reason for referral to the family 
renal genetics clinic 
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Clinical Diagnosis Gene 
Number 
of 
probands 
Diabetes insipidus AVPR2 3 
Joubert syndrome C5ORF42 1 
Joubert Syndrome  CEP290 1 
Autosomal dominant Alport syndrome  COL4A3 1 
X-linked Alport syndrome COL4A5 1 
Renal cysts and diabetes syndrome (RCAD) HNF1B 1 
Oro-facial-digital syndrome  OFD1 1 
Donnai-Barrow syndrome LRP2 1 
Autosomal Recessive Polycystic Kidney Disease 
(ARPKD) PKHD1 1 
Autosomal Dominant Tubulointerstitial Kidney 
Disease (ADTKD) MUC1 1 
Autosomal Dominant Tubulointerstitial Kidney 
Disease (ADTKD) REN 1 
Autosomal Dominant Tubulointerstitial Kidney 
Disease (ADTKD) UMOD 5 
Table 3.1 Known molecular genetic diagnosis prior to clinic 
  
  
55 
 
 
Reason	for	Referral	 Clinical	Diagnosis	 Gene	 Number	of	
probands		
Suspected	
ciliopathy	
syndrome	
Joubert	syndrome	 CC2D2A	 1	
Suspected	
ciliopathy	
syndrome	
Joubert	syndrome	 CEP290	 1	
Tubulopathy	 Bartter	syndrome	 CLCNKB	 1	
Familial	haematuria	 Autosomal	dominant	Alport	
syndrome		
COL4A3	 3	
Familial	haematuria	 Autosomal	dominant	Alport	
syndrome			
COL4A4	 4	
Familial	haematuria	 X-linked	Alport	syndrome	 COL4A5	 9*	
Congenital	
nephrotic	
syndrome	
Congenital	nephrotic	syndrome	 NPHS1	 1	
CAKUT	 Renal	coloboma	syndrome	 PAX2	 1	
Cystic	kidney	
disease	
Autosomal	dominant	polycystic	
kidney	disease	
PKD1	 4	
Tubulopathy	 Hypomagnesemia	with	secondary	
hypocalcemia	
TRPM6	 1	
Table 3.2 Confirmed clinical and molecular diagnosis following clinic visit  
*Includes one proband with a VUS (which segregated with phenotype) in COL4A5. 
Congenital anomalies of the kidney and urinary tract (CAKUT)     
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Figure 3.4 Family renal genetics clinic outcomes following clinic review 
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3.4. Discussion 
3.4.1. Stories from the clinic  
COL4A3, COL4A4 and COL4A5 genes 
The most common reason for referral was suspected familial haematuria, with 16 
probands being diagnosed with mutation in one of the COL4A3/4/5 genes making it 
the most common molecular diagnosis made post clinic visits. Families were 
identified with X-linked, autosomal dominant and autosomal recessive COL4A3/4/5 
disease. Taking a thorough family history and extended pedigree helped to predict 
the likely pattern of inheritance before being confirmed by molecular results. No 
common or founder mutations were observed in this cohort. COL4A3/4/5 variants 
identified were either previously reported as pathogenic mutations or were novel 
changes with predicted pathogenicity. However, in one proband, the molecular 
genetic tests result in COL4A5 variant with uncertain significance which required 
further segregation studies to confirm the pathogenicity and correlate genotype with 
phenotype. 
PKD1 and PKD2 genes 
Autosomal dominant polycystic disease (ADPKD) is a common disorder and usually 
can be easily identified and diagnosed (Rossetti and Harris, 2007). Despite that, in 
~1% of cases it can present early in life with renal cysts and missed diagnosed or 
confused with other congenital cystic kidney diseases. PKD1 and PKD2 genes were 
not routinely screened in probands with cystic kidney disease, however, individuals 
were tested when the clinical diagnosis was uncertain, there was an early onset 
presentation, or a precise molecular genetic diagnosis was needed for family 
planning decisions.  
A new molecular genetic diagnosis of PKD1 mutation was identified in four families. 
In two families, kidney cystic changes were recognized with early onset presentation 
of the disease. In both cases, the molecular genetic diagnosis helped other family 
members discover their options regard live-donor kidney transplantation and genetic 
screening.  
Another family was referred to the clinic with an 8-week-old child who had presented 
with a febrile illness and a renal ultrasound diagnostic of ADPKD. The molecular 
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genetic tests identified a truncating uni-allelic PKD1 mutation. This mutation believed 
to be de novo. The early recognition and genetic diagnosis of ADPKD in childhood 
permit the early detection and treatment of hypertension and maybe in the future it 
will allow the early use of disease modifying drugs such as tolvaptan and other novel 
therapies. 
CEP290 gene 
The diagnosis of CEP290 mutation was made in a family with retinal-renal-cerebellar 
syndrome (Joubert syndrome), a ciliopathy with broad phenotypic and genotypic 
spectrum. The proband had presented with visual loss, cystic kidney disease and 
rapid decrease in renal function. Providing the family with the precise molecular 
genetic diagnosis helped the family in decision making regarding family planning and 
renal transplantation. Moreover, it narrowed the planned investigations and allowed 
the patient to avoid invasive procedures such as renal biopsy. Percutaneous renal 
biopsy procedure complications are occasional yet serious and include haemorrhage 
requiring blood transfusion (0.9%), angiographic intervention (0.6%), and in very rare 
occasions nephrectomy (0.01%) and death (0.02%) (Corapi et al., 2012).   
PAX2 gene  
Many kidney diseases are syndromic with extra renal manifestations. The unique 
setting of the clinic facilitates thorough examination of probands and relatives giving 
enough time to explore renal and extra renal involvement. In 25 cases, excluding 
ADPKD, there were extra renal involvements include deafness, retinal defects, 
skeletal abnormalities, liver fibrosis and gout, all of which are pointing to rare 
syndromes. A previously reported family presented with autosomal dominant pattern 
of progressive renal failure, congenital renal dysplasia and a history of eye disease 
(Adam et al., 2013). A diagnosis of renal coloboma syndrome was proposed and the 
patient underwent ophthalmological examination which revealed optic nerve 
coloboma. The diagnosis was confirmed with PAX2 mutations segregating with the 
renal and eye phenotype Figure 3.5.  Once again, finding the precise molecular 
genetic diagnosis helped to identify at risk family members by mutation screening. In 
addition, mutation positive individuals were able to escape the invasive diagnostic 
renal biopsy and had targeted renal and ophthalmic investigation.  
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Figure 3.5 PAX2 Family pedigree and mutational analysis.  
(A) The family pedigree is shown. Males are represented by squares, females by 
circles. Half-shaded symbols indicated heterozygous mutation status. The proband is 
marked with an arrow. The genetic diagnosis in II:1 is presumed. (B) Sequence 
chromatograms of the wild-type and affected patient showing the heterozygous 
insertion mutation c.228_251dup, p.Ser77_Gly84dup within PAX2. 
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Clinical Diagnosis Gene Molecular Genetics 
X-linked Alport 
syndrome COL4A5 het c.2042G>T p.Gly681Val 
X-linked Alport 
syndrome COL4A5 het c.3454G>A pGly1152Ser 
X-linked Alport 
syndrome COL4A5 het c.4732A>T p.Ser1578Cys 
X-linked Alport 
syndrome COL4A5 
het c.3410G>C p.Gly1137Ala and 
c.3427G>A p.Gly1143Ser 
X-linked Alport 
syndrome COL4A5 hemi c.2801delC p.Pro934fs COL4A5 
X-linked Alport 
syndrome COL4A5 
hemi c.3410G>C p.Gly1137Ala and 
c.3427G>A p.Gly1143Ser in exon 
X-linked Alport 
syndrome COL4A5 het c.891+5G>A sequence changes 
X-linked Alport 
syndrome COL4A5 het c.4977-11_4977-5del 
X-linked Alport 
syndrome COL4A5 Hemi c.1396G>T  p.Gly466Ter 
AD Alport syndrome COL4A4 het c.3679G>A p.Gly1227Arg 
AD Alport syndrome COL4A4 het c.667_667insA, p.Gly223fs 
AD Alport syndrome COL4A4 het c.3052G>C p.Gly1018Arg 
AD Alport syndrome COL4A4 het c.81_86delACTCAT  p.Ile29_Leu30del 
AD Alport syndrome COL4A4 
COL4A3 
compound het COL4A3  c.1184G>A 
p.Gly295Glu and COL4A4  
c.4870_4873delGAAG p.Glu1624fs 
AD Alport syndrome COL4A4 
COL4A3 
compound het COL4A3 c.1184G>A 
p.Gly295Glu and COL4A4 
c.4870_4873delGAAG p.Glu1624fs 
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Clinical Diagnosis Gene Molecular Genetics 
AD Alport syndrome COL4A3 het c.1184G>A p.Gly395Glu 
Joubert syndrome CEP290 compound het c.2817G>T  p.Lys939Asn 
and c.2848dupC p.Gln950Profs*6 
Joubert syndrome CC2D2A compound het  c.2999A>T p.Glu1000Val 
and c.248-4.248-3 ins AAGTTTT 
Bartter syndrome CLCNKB compound het c.1481delA p.Gln494fs and 
c.512A>C p.His171Pro 
Congenital nephrotic 
syndrome NPHS1 homo c.3478C>T p.Arg1160X 
Renal coloboma 
syndrome PAX2 het c.228_251dup p.Ser77_Gly84dup 
ADPKD PKD1 het c.1967T>A p.Leu656Gln 
ADPKD PKD1 het c.8486T>A p.Val2829Glu 
ADPKD PKD1 het c.6487C>T p.Arg2163* 
Hypomagnesemia with 
secondary 
hypocalcaemia 
TRPM6 
compound het c.2391+6T>G and 
c.2562_2569dupGCTGTTCA p.Thr857fs 
Table 3.3 Molecular genetic diagnosis identified post clinic visit 
Autosomal dominant (AD), autosomal dominant polycystic kidney disease (ADPKD) 
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3.4.2. Lessons from the clinic 
The Newcastle family renal genetic clinic is not unique in the UK. Other clinics have 
been established in London (Adalat et al., 2010), Manchester and Cambridge with 
different renal genetic emphasis, for example the Cambridge clinic has an interest in 
kidney stones. These multidisciplinary clinics are increasingly required to facilitate 
the practise of personalised medicine. A report from Australia describes similar 
experience of multidisciplinary renal genetics clinic, where a confirmed molecular 
genetics tests provided a diagnosis in half of the referred cases (Mallett et al., 2016). 
The genetic testing also changed the diagnosis in around quarter referrals. In the 
age of genomics, such approaches facilitate the recognition, diagnosis and 
management of inherited disorders.  
Seeing the family together has great benefits. The physicians have the chance to 
observe different affected family members at the same setting. In some cases, they 
were able to identify the variable phenotype and incomplete penetrance. It also 
demonstrates the complexities of monogenic disorders, the difficulties genetic 
counsellors face in predicting long term prognosis for probands and affected 
relatives. Most important is being able to identify the most appropriate and 
informative individual in whom to start the investigation and the genetic testing. 
Later, cascade genetic screening proceeds in an effective manner, enabling 
confirmation of variants to be tested for segregation with disease phenotype in other 
family members. One more advantage of seeing the family together, is that 
specialist's advice and disease management plans are given the whole family at the 
same time avoiding receiving mixed messages when different individuals are seeing 
different specialists in isolation. In this way, a balanced and consistent report letter 
can be sent back to the referring doctor and the primary care physician. Families 
referred to the clinic are introduced to the most recent advances regarding 
management of the disease, disease support groups (local and international) and an 
opportunity to be recruited and involved in an active research project a rare disease 
programmes such as The National Registry of Rare Renal Disease ((RaDaR) 
www.rarerenal.org). 
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Setting up multidisciplinary clinic is costly in nature and may become more so given 
the expensive costs of the genetic tests. With the increased affordability of NGS, the 
cost of individual gene test is high compared to large panel and whole exome 
sequencing. The positive application of NGS in diagnosing cases with rare inherited 
kidney disorders is now easily recognised (Jacob et al., 2013, Shashi et al., 2014). 
Clinicians should also bear in mind the cost effect of frequent specialist visits, 
multiple and invasive investigations and hospital admissions that may be carried out 
among multiple members of the fame family without co-ordination, when following 
the traditional way of diagnosis. Attending the renal genetic clinic maximised the use 
of time for clinicians and families. Identifying a molecular genetic diagnosis in large 
family of affected patients and at-risk relatives limits the need for invasive, costly and 
unnecessary investigations in multiple family members.  
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3.5. Conclusion  
Inherited kidney diseases are rare disorders with lots of challenges including 
reduced quality of life, a prolonged diagnostic odyssey and their considerable effect 
on the health care system. Our renal genetic family clinic experience strongly 
emphasised the importance of attaining a precise molecular genetic diagnosis. 
Identifying a precise molecular genetic diagnosis has its beneficial value to both the 
patients and their physicians. It manifests in proper disease mechanism explanation, 
more accurate prediction of disease prognosis regarding renal function and extra 
renal manifestations. With a correct molecular diagnosis in hand, the investigation 
cascade to identify at risk relatives will be more focused, and non-relevant tests and 
invasive procedures can be avoided. It also allows for early management of the 
disease starting with life style modifications. When a clear diagnosis is developed in 
paediatric nephrology patient it will eventually ensure smoother and planned 
transition into adult nephrology services. To many families, having a firm diagnosis 
aids in family planning decisions through assisted reproductive medicine. In addition, 
when the prognosis of the disease required renal transplantation, healthy relative 
donors can be identified.  
Having the opportunity to study cohort of patients with inherited kidney disorders 
over a long period of time and successfully identifying the molecular genetic 
diagnosis broadens our understanding of the disease mechanisms, prognosis and 
outcomes. This also helps affected families to understand more fully their inherited 
disease and its implications to them and their family.  
The application of NGS technology gives more depth to the genetic tests, which by 
itself is meaningless if not combined with detailed and accurate phenotypic data 
attained by the clinicians. Genomic England’s future vision is to allow the practice 
and the feasibility of genomic medicine throughout the NHS services to reach 
efficient and precise molecular genetic diagnosis for a better clinical care. Despite 
the obstacles accompanying such genomic medicine programmes, the expected 
benefits can be enormous (Manolio et al., 2013).  
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Chapter 4  Whole Exome Sequencing Identifies a Novel Cause of 
Joubert Syndrome  
4.1. Introduction and aim 
Joubert syndrome (JBTS) is a neurodevelopmental ciliopathy with autosomal 
recessive inheritance, first described in 1969 (Joubert et al., 1969). The hallmarks of 
JBTS are the neurological phenotypes, characterised by hypotonia, abnormal eye 
movement (oculomotor apraxia), intellectual disability, truncal ataxia, and respiratory 
control dysfunction (sleep apnoea and/ or tachypnoea) (Boltshauser and Isler, 1977). 
A key diagnostic feature of JBTS is the presence of “the molar tooth sign” on the 
brain axial magnetic resonance imaging (MRI) (Poretti et al., 2014a). This 
pathognomonic abnormality arises from series of cerebellum and midbrain 
abnormalities; the hypoplasia and the dysplasia of the cerebellar vermis and of 
pontine and medullary structure, as well as the absence of decussation of the 
superior cerebellar peduncles and the pyramidal tracts.  
In a large cohort of JBTS patients, only 27% of the cases had purely neurological 
phenotype (Vilboux et al., 2017). Whereas, most of the cases were complicated by 
the extra neurological manifestations, which may present at different ages and 
ranges of severity (Kroes et al., 2016, Bachmann-Gagescu et al., 2015). Therefore, 
patients clinically diagnosed based on the presence of the molar tooth sign undergo 
serial thorough diagnostic examination and regular follow-up to assess and manage 
their multi-organ manifestations. The most common extra-neural manifestation are 
retinal defects, renal defects and hepatic defects. About 20-40% of JBTS patients 
develop renal involvement at any age in the form of nephronophthisis or cystic 
dysplastic kidneys, retinal dystrophy and blindness, hepatic involvement such as 
ductal plate malformation and fibrosis. More rare manifestation includes chorioretinal 
coloboma or optic nerve coloboma, dysmorphic facial features and/or skeletal 
involvement like dystrophy or polydactyly (Romani et al., 2013).  
Like other ciliopathies, JBTS exhibits noticeable genetic heterogeneity making the 
molecular genetic diagnosis of the disorder challenging. JBTS is caused by 
recessive mutations in more than 30 genes (http://omim.org), which are known to 
encode proteins localised to the primary cilium and its basal body. 
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Yet those identified genes explain the causative mutation in only 40-50% of JBTS 
cases (Valente et al., 2013a). Next generation sequencing (NGS), particularly whole 
exome sequencing (WES) studies, is a useful tool based on the complexity and 
heterogeneity of the disease to determine the genotype-phenotype correlation of 
JBTS, and equally to identify novel causative gene mutations (Vilboux et al., 2017). 
However, many cases of JBTS remain genetically unsolved. 
Here we used a combination of homozygosity mapping and whole exome 
sequencing, a valuable strategy for gene discovery to investigate an unsolved JBTS 
family. 
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Locus 
name 
Gene 
symbol 
Chromosome 
locus 
JBTS phenotype 
JBTS1 INPP5E 9q34.3 With or without colobomas, retinal or renal 
manifestations  
JBTS2 TMEM216 11q12.2 With retinal and renal manifestation; with or 
without polydactyly 
JBST3 AHI1 6q23.3 With retinal manifestation; with or without renal 
manifestation 
JBTS4 NPHP1 2q13 With retinal and renal manifestation 
JBTS5 CEP290 12q21.32 With retinal and renal manifestations 
JBTS6 TMEM67 8q22.1 With renal and hepatic manifestation  
JBTS7 RPGRIP1L 16q12.2 With renal manifestation; with hepatic 
manifestation 
JBTS8 ARL13B 3q11.1-q11.2 With or without retinal manifestation 
JBTS9 CC2D2A 4p15 With or without retinal manifestations; with 
hepatic manifestation; renal manifestations 
JBTS10 OFD1 Xp22.2 With or without retinal manifestation 
JBTS11 TTC21B 2q24.3 With renal manifestation  
JBTS12 KIF7 15q26 Classic JBTS with dysmorphism and 
polydactyly 
JBTS13 TCTN1 12q24.11 With or without retinal manifestation 
JBTS14 TMEM237 2q33.1 With renal manifestation 
JBTS15 CEP41 7q32.2 Classic JBTS with polydactyly and coloboma: 
with or without retina, renal or hepatic 
manifestation  
JBTS16  TMEM138 11q12 With retinal and renal manifistations 
JBTS17 C5orf42 10q24 Classic JBTS with or without polydactyly  
JBTS18 TCTN3 10q24.1 Classic JBTS with or without OFD features  
JBTS19 ZNF423 16q12.1 With retinal and renal manifestations 
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Locus 
name 
Gene 
symbol 
Chromosome 
locus 
JBTS phenotype 
JBTS20 TMEM231 16q23.1 With retinal and renal manifestations 
JBTS21 CSPP1 8q13.1-q13.2 With or without retinal or renal manifestations 
JBTS22 PDE6D 2q37.1 With retinal and renal manifestations 
JBTS23 KIAA0586 14q23.1 Classic  JBTS 
JBTS24 TCTN2 12q24.31 Classic JBTS 
JBTS25 CEP104 1p36.32 Classic JBTS  
JBTS26 KIAA0556 16p12.1 With midline orofacial deformity 
JBTS27  B9D1 17p11.2 Classic JBTS 
JBTS28 MKS1 17q22 Classic JBTS; with retinal manifestation  
JBTS29 TMEM107 17p13.1 With retinal and hepatic manifestations 
JBTS30 ARMC9 2q37.1 With polydactyly and retinal manifestation 
JBTS31 CEP120 5q23.2 Classic JBTS 
JBTS32 SUFU 10q24.32 Classic JBTS with polydactyly and 
dysmorphism  
JBTS33 PIBF1 13q21.3-
q22.1  
With retina, renal or hepatic manifestations 
JBTS34 B9D2 19q13.2 With skeletal manifestation and dysmorphism 
Table 4.1 Summary of genes causing Joubert syndrome, their locus and 
phenotype 
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4.2. Materials and methods 
All patients and their relatives consented to this study. Ethical approval was obtained 
from the UK National Research Ethics Service (NRES) Committee Northern and 
Yorkshire (09/H0903/36) and NRES Committee North East – Newcastle and North 
Tyneside 1 (08/H0906/28+5). Following informed and written consent, blood samples 
or mouth swaps were obtained from affected patients and their relatives.   
Genomic DNA (2 µg) from three affected siblings and their parents was subjected to 
whole exome paired-end sequencing analysis with 100× coverage by generating 51 
Mb Sure Select V4 libraries (Agilent Technologies, USA). The sequence reads were 
run on a HiSeq2500 platform (Illumina, San Diego, CA, USA). Ingenuity Variant 
Analysis web-based application and Homozygosity Mapper 
(http://www.homozygositymapper.org/) was used for data analysis. The variant of 
interest was further tested for likely pathogenicity using in silico prediction tools 
(Mutation taster, SIFT, PolyPhen2, and CADD). Selected variant was further 
considered and validated by Sanger sequencing in all available family members to 
confirm segregation with disease status. 
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4.3. Results 
4.3.1. Clinical features of JBTS family 
A consanguineous family, who originated from Pakistan, consisted of healthy parents 
and six children, including three affected siblings who had clinically diagnosed with 
JBTS. The eldest sibling (II:1) a 21-year-old female, presented during early 
childhood (aged 4years) with night blindness progressed to bilateral visual loss. 
Table 4.2. Later, she developed ataxia, developmental delay and complained of 
frequent attacks of urinary tract infections. She also reported thermoregulation 
problems and an episode of transverse myelitis. Her clinical investigation showed 
evidence of renal scarring and her brain MRI revealed the molar tooth sign that is 
pathognomonic of JBTS Figure 4.1. The other two affected sisters (II:4 and II:5) had 
a very similar presentation with neurodevelopmental delay and retinal dystrophy. II:4 
is a 12-year-old female with developmental delay, ataxia, sleep apnoea, progressive 
visual loss, night blindness and thermoregulation problems. Her past medical history 
did not reveal any renal complaint and her renal ultrasound was normal. II:5 is a 9-
year-old female with developmental delay, ataxia, sleep apnoea, progressive visual 
loss, and night blindness; furthermore, she developed oculomotor apraxia. Just like 
her oldest sister, she experienced recurrent attacks of UTI and the renal ultrasound 
reported unequal sized kidneys. An axial image of the brain MRI showed the 
pathognomonic molar tooth sign in the three affected sisters. To further investigate 
the three siblings’ eye phenotypes, retinal fundal examination was conducted Figure 
4.2. Coloured fundal photographs of the eyes showed granular alterations of retinal 
pigment epithelium with subtle spicule formation particularly around major vascular 
arcades (particularly in oldest sibling II:1) and arteriolar attenuation. Additionally, 
autofluorescent retinal images displayed stippled hypo-autofluorescent areas 
concentrated around the arcades, particularly the inferior arcades seen clearly in 
youngest sibling II:5. By contrast, ring of hyper-autofluorescence was noted around 
fovea in II:4 and II:5. Horizontal optical coherence tomography scan was applied and 
demonstrated thinning of outer nuclear layer and loss of ellipsoid and external 
limiting membrane lines with preservation of inner retinal lamination in all three 
siblings. 
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  II:1 II:4 II:5 
Age (years) 21  12 9 
Central Nervous 
symptoms  
Developmental 
delay, ataxia 
Developmental 
delay, ataxia 
Developmental 
delay, ataxia 
Ocular symptoms  
  
Rod cone 
dystrophy, night 
blindness, 
progressive visual 
loss 
Rod cone 
dystrophy, night 
blindness, 
progressive visual 
loss 
Rod cone 
dystrophy, night 
blindness, 
progressive visual 
loss, oculomotor 
apraxia 
eGFR 
(mL/min/1.73m2) 
75 >90 >90 
Renal symptoms Recurrent UTI None Recurrent UTI 
USS Renal Renal scarring 
bilaterally 
Normal USS Unequal kidney 
size 
Other Thermoregulation 
problems; 
episode of 
transverse myelitis 
Thermoregulation 
problems; 
sleep apnoea 
  
Table 4.2 Clinical features of JBTS in affected family members 
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Figure 4.1 Axial brain MRI of the affected siblings.  
Images showing the appearance of the cerebellar vermis the “molar tooth sign”, 
presenting as a deepened interpeduncular fossa and thickened, elongated superior 
cerebellar peduncles. 
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Figure 4.2 Retinal phenotypes in 3 JBTS affected siblings 
 (i): Colour fundal photographs of the eyes showing granular alterations of retinal 
pigment epithelium with subtle spicule formation particularly around major vascular 
arcades (particularly in oldest sibling, A&B) and arteriolar attenuation.  
(ii): Blue autofluorescent images with stippled hypo-autofluorescent areas 
concentrated around the arcades, particularly the inferior arcades seen clearly in 
youngest sibling (F). Ring of hyper-autofluorescence around fovea in middle and 
youngest siblings (E and F respectively).  
(iii): Horizontal optical coherence tomography scans (50 degree in H, and 30 degree 
in I &J) demonstrating thinning of outer nuclear layer and loss of ellipsoid and 
external limiting membrane lines with preservation of inner retinal lamination in all 
three siblings. 
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4.3.2. Molecular genetics investigation of JBTS family  
Molecular genetic investigations were performed including whole exome sequencing 
and variant analysis combined with homozygosity mapping. This approach was 
taken rather than targeted ciliopathy gene panel as the gene panel was not 
representative of recently identified genes. The whole exome sequencing in the 
affected index case was analysed for variants in all known JBTS genes using 
Ingenuity Variant Analysis software. This did not reveal a likely deleterious biallelic 
variant in any of the known JBT-related genes (JBTS1-34). Homozygosity mapping 
in two affected cases (II:4 andII:5) identified four shared regions of homozygosity on 
chromosome 6, 10, 16 and 18. A thorough re-analysis was performed using 
combined WES data of two affected siblings and their unaffected parents (II:4, II:5, 
I:1 and I:2) considering exome variants spanning the shared homozygous region 
with a potential link to a ciliopathy phenotype Table 4.3. One single previously 
unreported homozygous variant was identified on chromosome 10 locus (chr10: 
101569997-109106128 (hg19)) a homozygous nucleotide substitution lead to 
missense mutation in exon 5 of ARL3, encoding ARL3 a small GTPase, and causing 
a single nucleotide change c.446G>A, leading to alteration in the protein coding 
sequence, arginine to histidine p. Arg149His. ARL3 gene is a small target for genetic 
variation, its protein product consisting of 182 amino acid only. (Ref sequence 
NM_004311.3: c.446G>A, p.(Arg149His)). No other pathogenic homozygous alleles 
were found in all the three affected individuals. The ARL3 R149 residue is highly 
conserved throughout evolution in all species except D. melanogaster and in silico 
prediction tools suggest that the missense change is likely to be pathogenic Table 
4.4.  
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Figure 4.3 Genome wide homozygosity mapping in affected siblings II:4 and 
II:5.  
The standard plot of homozygosity score (Y axis) and genomic region chromosomes 
1-22 (X axis). The regions with excess homozygosity compared to control population 
are shown as red bars and the shared regions of homozygosity between the two 
siblings are marked with blue arrows.  
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Affected member* II:4 II:5 
Number of variants  145724 144048 
Variants of high confidence 130033 128453 
SNVs/Indel ≤ 1% in HapMap18 and  
1000 Genome database 
7213 7038 
Predicted deleterious 1066 800 
Biological Context (Known JBTS genes) 0 0 
Biological Context (Primary cilia / ciliopathies) 22 3 
Homozygous predicted pathogenic alleles  1 1 
Table 4.3 Filtering criteria used for single nucleotide variants (SNVs) and 
insertion and deletion selection (Indels).  
*Affected	members	after	screening	of	kindred	based	on	clinical	features. 
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Figure 4.4 Molecular genetic investigation of JBTS family. 
(A) A screenshot of Qiagen Integrated Variant Analysis software demonstrating 
ARL3 homozygous allele in two affected siblings and a het allele in both parents.  
(B) Genomic and exon structure of ARL3 with the homozygous mutation R149H in 
exon 5 shown.  
(C) Evolutionary conservation of R149 amino acid residue (highlighted in red).  
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To confirm segregation of ARL3 variant, we Sanger sequenced all three affected 
individuals (I:1, II:4 and II:5), their healthy parents (I:1 and I:2) and their three 
unaffected siblings.  Sanger sequencing confirmed that the mutation was present in 
all three affected children and segregated from both parents. The mutations were 
homozygous in the three affected siblings, heterozygous in the parents and one 
unaffected sister, and wild type in another two unaffected siblings Figure 4.5.  
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Figure 4.5 Sanger sequencing confirmation of segregation of ARL3 mutation.  
a. The pedigree of JBTS family showing the number of the affected siblings and the 
outcome of segregation analysis; affected (shaded), carriers (half shaded) and 
wild-type (unshaded). 
b. Sequence chromatogram of all family members. (A) Showing homozygous 
variant in affected siblings, (B) showing heterozygous variants in carrier parents 
and one sibling and (C) showing wild type variant in unaffected siblings.   
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4.4. Discussion 
Here we used a combination of homozygosity mapping and WES to investigate an 
unsolved family with JBTS phenotype with predominantly brain and retinal 
phenotype. Molecular genetic data analysis on our JBST family revealed a novel 
homozygous missense mutation in ARL3 gene, a homozygous missense mutation 
Arg149His. In silico tools showed the variant pathogenicity ant the ExAC Browser 
and gnomAD do not have any homozygous pathogenic variants reported within 
ARL3 and that the gene is relatively intolerant to variation (positive Z score of 0.44). 
The mutation was confirmed using Sanger sequencing to be homozygous in the 
affected siblings, heterozygous in the parents and another sibling, and wild type in 
two other healthy siblings.  ARL3 gene belongs to the group of small GTPases, 
localises to the cilium and has main prole in ciliary protein trafficking. ARL3 functions 
as molecular switch by binding and hydrolyzing GTP during cellular processes, they 
bind to many lipid-modified protein complexes to control their localisation (Zhang et 
al., 2013).  The small GTPase is switched on by guanine nucleotide exchange factor 
(GEF) namely the cilia specific protein ARL13B, then binds to its effectors which are 
lipid-modified proteins (Gotthardt et al., 2015). In the pre-ciliary compartment, it’s 
then switched off by a GTPase-activating factor (GAP) namely Retinitis protein 2 
(RP2) (Ismail et al., 2012).  
GTPase role in ciliary protein trafficking has been recently recognised, two members 
of this family are known to be mutated in human ciliopathies, Bardet-Biedl syndrome 
(ARL6) (Fan et al., 2004) and Joubert syndrome (ARL13B) (Cantagrel et al., 2008). 
To date, no mutations in ARL3 reported to cause a human ciliopathy disorder, 
however, heterozygous missense variant of ARL3 was reported by Strom et al. 
(2016) in a Caucasian family with non-syndromic retinitis pigmentosa. On the other 
hand, Arl3 knockout mice show typical ciliopathy manifestation with renal, hepatic 
and pancreatic cysts formation, impaired photoreceptors development and failure to 
thrive beyond 3 weeks of age (Schrick et al., 2006). Studies in C. elegance and 
Leishmania, showed ciliary localisation of Arl3 and intraflagellar transport disruption 
when mutated (Cuvillier et al., 2000, Li et al., 2010). ARL3 has many known effectors 
(Wright et al., 2011). When activated, ARL3 binds to a specific effector that carries 
ciliary cargo. ARL3 binds to the cargo-carrier protein complex at the transitional zone 
causing conformational changes and unloading the ciliary cargo Figure 4.6.  
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Figure 4.6 A model for sorting and shuttling of lipid modified ciliary cargo into 
the cilia.  
The GDI-like solubilizing factor (GSF) (blue; e.g. Unc119b) binds to the lipid-modified 
tail of the ciliary cargo (green). This is transported to the cilium, whereby Arl3, 
maintained in a GTP-bound state by Arl13b, binds the GSF, forcing a conformational 
shift, which releases the ciliary cargo to the ciliary membrane. Binding of Arl3 to the 
GAP RP2 results in an inactive, GDP-bound state. 
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Several investigators from Europe and North America were asked to screen their 
cohorts of patients for similar gene findings. Researchers contacted were Friedhlem 
Hildebrant, Rachel Giles, Sophie Saunier and Dan Doherty. Gene data were posted 
on GeneMatcher (https://www.genematcher.org/) to find other families, but we didn’t 
have a response.  
We finally reached a group in Saudi Arabia at King Faisal Specialist Hospital and 
Research Centre led by senior specialist Fowzan AlKuraya, who had a cohort of 35 
unsolved JBTS-affected individuals. After screening their WES databases for our 
proposed gene ARL3, they found a single previously unreported homozygous 
missense variant in ARL3 in an index individual, causing a single nucleotide change 
c.446G>A, leading to alteration in the protein coding sequence, arginine to cystine p. 
Arg149Cys and fully co-segregated with the JBTS phenotype in the family Figure 
4.8. No additional ARL3 pathogenic variants were identified in their WES databases, 
which are relatively enriched with autozygosity Figure 4.7. 
The Saudi Arabian family comprising first-cousin healthy parents and six children, 
including the 5-year-old male index individual (II:5). He presented with 
developmental delay, multicystic dysplastic left kidney Figure 4.9.D, night blindness, 
and mild dysmorphic features, including ptosis Figure 4.9.B. His MRI of the brain 
showed severe vermis hypoplasia with abnormal thick cerebellar peduncles 
configured in the shape of a typical molar tooth sign Figure 4.9.C, as well as 
abnormal configuration of the midbrain, thinning of the pontomesencephalic junction 
and midportion of the midbrain, and mild decreased brain volume with a paucity of 
white matter in the frontotemporal region and dilated ventricular system.  
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Figure 4.7 . Genome wide homozygosity mapping of patient in the two JBTS 
families 
The plot showing the shared homozygous region between the affected members of 
the two families on chromosome 10 (blue rectangle). Regions of homozygosity are 
shown in red and the position of ARL3 is marked with black arrow. 
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Figure 4.8 Molecular genetics investigations of the two JBTS families 
(A) Schematic representation of nucleotide changes within ARL3 both leading to the 
homozygous missense mutations affecting Arg149 residue (Arg149Cys and 
Arg149His) are located in exon 5. 
(B) Sequence chromatogram of the two different mutations in ARL3 identified. 
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Figure 4.9 Clinical and radiological images to the affected member of 2nd 
family  
(A) The Pedigree family 2 showing the affected index (arrow) and the outcome of 
segregation analysis (affected (shaded) and carriers (half shaded). 
(B) Facial photo of the index family 2 (II:5) showing the mild dysmorphic feature and 
ptosis. 
(C) Brain MRI images of the index family 2 (II:5) showing evidence of molar tooth 
sign - cerebellar vermis hypoplasia and elongation of superior cerebellar 
peduncles 
(D) and (E) Ultrasound image of the kidney of the affected member family 2 (II:5) 
showing the echogenic multicystic dysplastic in the left kidney (D) and normal 
right kidney (E). 
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Chapter 5  Characterization of Novel ARL3 Homozygous Mutation 
Causing Joubert Syndrome 
5.1. Introduction and aim  
ADP ribosylation factor (ARF)–like proteins (ARLs) are enzymatically active small 
GTP-binding proteins (G proteins) in the Ras superfamily. ARLs G-proteins family 
include 16 members, and the role of most ARLs is to regulate the assembly of multi-
protein complexes by regulating protein membrane trafficking and phospholipids 
composition (Kahn et al., 2005). Small G proteins are considered molecular switches 
cycling between a GTP-bound 'on' and a GDP-bound 'off' states which activate and 
inactivate, respectively, the G protein (Cherfils and Zeghouf, 2013) leading to 
conformational changes at the switch region where the effector binds. Small G 
proteins are switched on by a guanine nucleotide exchange factor (GEF) and cannot 
hydrolyse GTP in the absence of a GTPase-activating protein (GAP). GEF and GAP 
modulators are found to be distinct and exclusive against each ARL protein. Unlike 
other small G proteins, the ARLs have an N-terminal amphipathic helix instead of 
lipid modification at the C terminus (Burd et al., 2004, Gillingham and Munro, 2007).	
The GTP-bound active G protein functions through interaction with specific effectors 
involved in trafficking of lipid-modified proteins.	When binding to GTP, a loop of beta 
sheets between the switch region is formed, called the interswitch, displacing the N-
terminal amphipathic helix from hydrophobic pocket and promoting insertion of the 
helix into an adjacent bilayer, facilitating protein trafficking (Donaldson and Jackson, 
2011).  
ARL3 is a soluble, small G protein that has been identified in all ciliated organisms 
and localizes to the cilium and centrosome. ARL3 found to be colocalised with its 
effector RP2 and PDED at different parts of photoreceptors, cell body, inner segment 
and connecting cilium (Grayson et al., 2002) (Zhang et al., 2004). ARL3 has major 
role in cytokinesis and cilia signalling (Zhou et al., 2006). ARL3 is regulated by its 
GEF ARL13B, cilia-specific protein when mutated in human gives rise to JBTS with 
retinopathy. ARL3 also regulated by its GAP RP2, a pre-ciliary protein when mutated 
in human leads to X-linked non syndromic retinitis pigmentosa (Veltel et al., 2008). 
ARL3 human heterozygous mutation has been previously reported in patient with 
retinal dystrophy. While a loss of biallelic ARL3 loss of function in mice leads to 
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typical ciliopathy phenotype with severe manifestations (Schrick et al., 2006).   
Among ARL3 effectors are the Guanosine nucleotide Dissociation Inhibitor (GDI) 
GDI-like solubilizing factors (GSFs) PDE6D, UNC119A, and UNC119B, whose 
function to solubilise and transport post translational lipidated proteins. GSF release 
of lipidated cargo protein is ARL3- GTP dependent (Ismail et al., 2012, Ismail et al., 
2011). The segregation of ARL3 regulators GEF (cilia specific ARL13B) and GAP 
(pre-ciliary RP2) are thought to generate an ARL3-GTP gradient inside the cilium 
ensuring the specific release of lipidated cargo protein, solubilised by GSFs, in the 
cilia (Gotthardt et al., 2015). 
We aim to study the impact of ARL3 variant Arg149 on the mechanism of ARL3-
ARL13B interaction, to investigate the structural and the functional effect of the ARL3 
Arg149His variant on patient fibroblasts.  
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5.2. Results 
5.2.1. Homology models of ARL3-ARL13B complex 
To study the effect of ARL3 variant detected on the interaction of ARL13B with 
ARL3, a homology modelling study was performed. Human ARL3 and ARL13B were 
modelled on the crystal structure of the Arl3-Arl13B complex from Chlamydomonas 
reinhardtii. ARL3 conserved variants were located at the in a loop between α4 and 
β6 domains and predicted to interrupt the ARL3-ARL13B interaction. ARL3 precise 
residue (Arg149) is essentially required for the interaction with its GEF ARL13B 
conserved residue (Glu88).  Superimposition of the crystal structures of ARL3 in 
complex with its known interactors UNC119A and BARTL1, the GAP RP2, and GEF 
ARL13B, showed exclusive CrARL13B-CrARL3 complex interface interaction 
between the conserved residues ARL3 (Arg148) and ARL13B (Glu86). Figure 5.1.b 
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Figure 5.1 Homology models of ARL3-ARL13B complex  
The Human ARL13B-ARL3 Complex Is Predicted to Involve an Interaction between 
Evolutionarily Conserved Glutamate and Arginine Residues 
(A) Partial amino acid sequence alignments of the ciliary GEF, ARL13B, and ARL3. 
Highlighted in red are the evolutionarily conserved glutamate residue located in the 
switch II domain of ARL13B (E86 [Glu86] in C. reinhardtii ARL13B [CrARL13B]) and 
the arginine residue in the loop region between the α4 and β6 domains of ARL3 
(R148 [Arg148] in CrARL3). 
(B) Superimposition of the crystal structures of ARL3 (gray) in complex with 
its known interactors: the effectors UNC119A (salmon; PDB: 4GOJ) and BARTL1 
(yellow; PDB: 4ZI2), the GAP RP2 (orange; PDB: 3BH6), and GEF ARL13B (blue; 
PDB: 5DI3). On the right side is a zoomed-in view of the salt bridge between Glu86 
and Arg148 at the CrARL13B-CrARL3 complex interface. 
  
B 
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5.2.2. Functional investigation of ARL3-ARL13B interaction mechanism  
To functionally investigate the effect of ARL3 mutation on the interaction with 
ARL13B, a florescence-based polarisation experiments were carried by our 
collaborators at the Structural Biology of Cilia Lab, Beatson Institute for Cancer 
Research, Glasgow. Human ARL3 wild-type (WT) or mutant (R149H) were bound to 
fluorescently-labelled GDP, and an excess of unlabelled GTP was added in the 
presence or absence of ARL13B. The capability of nucleotide exchange was then 
tracked for both versions of the protein by recording the fluorescence polarisation 
over time. When adding ARL13B GEF, wild-type ARL3 showed clear acceleration of 
nucleotide exchange activity. Whereas, under similar conditions, mutant ARL3 
R149H failed to show acceleration of the nucleotide exchange in the presence of 
ARL13B Figure 5.2.A. To confirm our results, the highly conserved C. reinhardtii 
ARL3 wild-type and mutant R148H proteins were used under similar conditions. 
Wild-type CrARL3 showed clear acceleration of nucleotide exchange activity, while, 
mutant CrARL3 R148H failed to show acceleration of the nucleotide exchange in the 
presence of CrARL13B Figure 5.2.B. The integrity of the mutant protein was 
confirmed using GST pull-down study, where both WT and R149H ARL3 proteins 
were pulled down equally by UNC119A Figure 5.2.D. To further study the ARL3-
ARL13B interaction, we performed a reverse charge mutation E86R in ARL13B, 
using C. reinhardtii proteins. As we predicted, mutant CrARL13B E86R failed to 
accelerate the nucleotide exchange of wild type CrARL3 Figure 5.2.C.   
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Figure 5.2 Functional investigation of ARL3-ARL13B interaction.  
(A) Assay of GEF activity for murine WT ARL3 (ARL3WT) and R149H ARL3 
(ARL3R149H). Fluorescence polarization was measured for 1 µM mantGDP-loaded 
ARL3, to which 400 µM GppNHp and 5 µM H. sapiens ARL13B (HsARL13B) were 
added. Nucleotide exchange was shown by only ARL3WT.  
(B) Assay of GEF activity with fluorescence polarization measurements of 0.5 µM 
mantGDP-loaded CrARL3WT and CrARL3R148H, to which 10 µM GppNHp (GTP 
analog) and 5 µM CrARL13B⋅GppNHp were added at the indicated time points. Only 
CrARL3WT showed nucleotide exchange, as indicated by the drop in fluorescence 
polarization.  
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(C) Assay of GEF activity with fluorescence polarization measurements of 0.5 µM 
mantGDP-loaded CrARL3WT and 5 µM CrARL13B⋅GppNHpWT or CrArl13bE86R, 
to which 10 µM GppNHp (GTP analog) was added at the indicated time points. Only 
CrArl13bWT showed nucleotide exchange, as indicated by the drop in fluorescence 
polarization.  
(D) 30 µg of full-length UNC119A-GST was used to pull down 60 µg of murine 
ARL3WT and ARL3R149H that were loaded with the GTP analog GppNHp. Proteins 
were detected on immunoblots with anti-GST (red) and anti-His (green) antibodies. 
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5.2.3.  Structural analysis of the ARL3 mutation variant in patients 
To determine the effect of the ARL3 mutation variant detected at the cellular level, 
ciliary morphology was studied in human patients. Fibroblasts were isolated from 
skin biopsies obtained from all three affected individuals in JBTS family (II:1, II:4 and 
II:5) in addition to controls (both parents (I:1 and I:2) and an unaffected sibling (II:3)). 
Evaluation of percentage of ciliation, cilia length and morphology were performed 
after 48 h of serum starvation. 
Figure 5.3.b  
Cilia were identified based on ARL13B antibody staining. No significant difference in 
percentage of ciliation rate found between affected (mean = 75.7, 86.8 and 81% in 
II:1, II:4 and II:5, respectively) and controls (mean = 90.3, 84.25 and 83.6% in I:1, I:2 
and II:3, respectively). Mutant fibroblasts showed variable ciliary lengths (mean 
length = 5.9, 7.8, and 6.8 µm in II:1, II:4, and II:5, respectively)  compared to the 
steady ciliary length reported in the control (mean length = 5.7, 6.0 and 6.1 µm in  
I:1, I:2 and II:3, respectively) with no significant differences between the two groups. 
Figure 5.3 
Scanning electron microscopy (EM) on patients and control fibroblasts confirmed the 
previous findings of no significant changes in cilia length. Figure 5.4. EM images 
also showed no difference in the structural appearance of the primary cilia.  
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Figure 5.3 Immunofluorescence analysis of cilia length in ARL3 mutant and 
control fibroblasts.  
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(A) Fibroblasts from affected individuals (II:1, II:4 and II:5) and controls (I:1, 
I;2, II:3) were imaged using immunofluorescence microscopy following 
staining with anti-ARL13B (red) to identify ciliary membrane, anti-
PERICENTRIN (magenta) to identify the ciliary base and DAPI (blue) 
to identify the cell nucleus. Scale bar = 10 µm.  
(B) Quantification of cilia length from affected and control fibroblasts (n.s. 
not significant, ANOVA, n > 30 cilia in each group).  
(C) Percentage ciliation rate in affected and control fibroblasts (n.s. not 
significant, ANOVA, n > 90 cells in each group). 
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Figure 5.4 Scanning electron microscopy (SEM) and quantification of cilia 
length in ARL3 mutant and control fibroblasts  
(A) Fibroblasts from affected individuals (II:5, II:4, II:1) and controls (I:1, I;2, II:3) 
seen under SEM reveal normal appearances of primary cilia (Scale bar 2 µm).  
(B) Dot plot to show quantification of SEM cilia length, bars represent mean (n.s. not 
significant, ANOVA, n = 10 cilia in each group). 
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5.2.4. Functional analysis of the ARL3 mutation variant in patients  
Protein trafficking to primary cilia is mediated by several small GTPases. Lipidated 
cargo proteins are post-translationally modified either carrying hydrophobic myristoyl 
group to N-terminal or internal glycine residues of protein or carrying prenyl group to 
C-terminal cysteine(s) of the target protein.  While the myristoyl and prenyl motifs 
facilitates protein anchoring to cell membrane, GSF carrier proteins are required to 
facilitate their transport. The key role for ARL3-GTP, its GAP (RP2), and GEF 
(ARL13B) in trafficking of lipidated cargo proteins is the docking of cargo-carries 
complex at proper membrane destination. ARL3 functions as an allosteric release 
factor of all GSFs members: PDE6D, UNC119A/B. PDE6D is involved in trafficking 
of prenylated proteins, while UNC119A/B traffics myristoylated proteins (Gotthardt et 
al., 2015).  
ARL3 exerts its function as a release factor only when bound to GTP during the 
ARL3-ARL13B interaction. Since we concluded that ARL3 mutation variant R149H 
disrupts this interaction, we predicted the ciliary localization of GSF cargo to be 
decreased. The prenylated GSF ciliary cargo includes INPP5E, GRK1, and PDE6 
catalytic subunits (Fansa et al., 2016), whereas the myristoylated ciliary cargo 
includes NPHP3, GNAT1, and Cystin1 (Jaiswal et al., 2016).  
We considered to study INPP5E ciliary localisation to represent the prenylated cargo 
proteins. After 48 hours of serum starvation, fibroblasts from affected individuals 
(II:5, II:4, II:1) and controls (I:1, I:2, II:3) were fixed and stained with antibodies 
directed towards INPP5E, PERICENTRIN as basal body marker, ARL13B as ciliary 
marker, and DAPI as a nuclear marker Figure 5.5. INPP5E ciliary intensity was 
calculated and corrected to background staining using ImageJ software Figure 5.6. 
Immunofluorescence microscopy analysis of total cilia INPP5E intensity in ARL3 
mutant cilia demonstrated a significant loss of INPP5E content compared to control 
cilia. Yet the results were variable among each group, total cilia INPP5E in control 
fibroblast (II:3) cilia was higher than in heterozygous fibroblast (I:1 and II:2) cilia 
Figure 5.7.  
We examined NPHP3 ciliary localisation to represent the myristoylated cargo 
proteins. After 48 hours of serum starvation, fibroblasts from affected individuals 
(II:5, II:4, II:1) and controls (I:1, I:2, II:3) were fixed and stained with antibodies 
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directed towards NPHP3, PERICENTRIN as basal body marker, ARL13B as ciliary 
marker, and DAPI as a nuclear marker Figure 5.8. NPHP3 ciliary intensity was 
calculated and corrected to background staining using ImageJ software Figure 5.9. 
Using the NPHP3 antibody we noted both ciliary and cellular (mostly nuclear) 
staining. The cellular staining does not seem to correspond to genotype and is likely 
to be non-specific. As expected, the immunofluorescence microscopy analysis of 
total cilia NPHP3 intensity in ARL3 mutant cilia confirmed a significant loss of 
NPHP3 content compared to control cilia Figure 5.10.   
Our data validated the role of ARL3 in the release of both prenylated and 
myristoylated ciliary cargo proteins. We proved that this function is disrupted by the 
ARL3 Arg149His mutation and that WT ARL3 is required for normal release of these 
cargos into the ciliary axoneme. 
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Figure 5.5 Immunofluorescence analysis of cilia INPP5E content in ARL3 
mutant and control fibroblasts.  
Fibroblasts from affected individuals (II:1, II:4 and II:5) and controls (I:1, I:2, II:3) 
were fixed and stained with antibodies directed towards PERICENTRIN (magenta), 
ARL13B (red), INPP5E (green) and DAPI (blue) as a nuclear marker. Representative 
individual images are shown for PERICENTRIN, ARL13B and INPP5E as well as 
overlay images at high and low power. Scale bar = 10 µm. 
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Figure 5.6 INPP5E content in fibroblast cilia 
Zoomed overlay images of fibroblast primary cilia from affected individuals in family 2 
(II:5, II:4, II:1) and controls (I:1, I:2, II:3) were fixed and stained with antibodies 
directed towards PERICENTRIN (magenta), ARL13B (red), and INPP5E (green) and 
DAPI (blue) as a nuclear marker.   
 
 
 
Figure 5.7 Quantification of ciliary localization of INPP5E  
(A) Quantification of ciliary localization of INPP5E in each affected (II:1, II:4 and II:5) 
and controls (I:1, I:2, II:3). 
(B) Quantification of ciliary localization of INPP5E in affected and controls groups 
(∗∗∗∗p < 0.0001, unpaired t test, n > 150 cilia for each group). 
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Figure 5.8 Immunofluorescence analysis of cilia NPHP3 content in ARL3 
mutant and control fibroblasts.  
Fibroblasts from affected individuals (II:1, II:4 and II:5) and controls (I:1, I:2, II:3) 
were fixed and stained with antibodies directed towards PERICENTRIN (magenta), 
ARL13B (red), NPHP3 (green) and DAPI (blue) as a nuclear marker. Representative 
individual images are shown for PERICENTRIN, ARL13B and NPHP3 as well as 
overlay images at high and low power. Scale bar = 10 µm.  
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Figure 5.9  NPHP3 content in fibroblast cilia 
Zoomed overlay images of fibroblast primary cilia from affected individuals in family 2 
(II:5, II:4, II:1) and controls (I:1, I:2, II:3) were fixed and stained with antibodies 
directed towards PERICENTRIN (magenta), ARL13B (red), NPHP3 (green) and 
DAPI (blue) as a nuclear marker. 
 
 
 
Figure 5.10 Quantification of ciliary localization of NPHP3  
(A) Quantification of ciliary localization of NPHP3 in each affected (II:1, II:4 and 
II:5) and controls (I:1, I:2, II:3).  
(B) Quantification of ciliary localization of NPHP3 in affected and controls groups 
(∗∗∗∗p < 0.0001, unpaired t test, n > 150 cilia for each group).  
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To further confirm our previous finding to be specific to the loss of ARL3 function as 
an allosteric release factor of all GSFs members, we studied intraflagellar transport 
(IFT) and Sonic Hedgehog signal transduction. We examined the ciliary content of 
another protein, GLI3, known to be translocated independently of the GSF transport 
(Haycraft et al., 2005). After 24 hours of serum starvation, fibroblasts from affected 
individuals (II:5, II:4, II:1) and controls (I:1, I:2, II:3) were treated with Sonic 
Hedgehog pathway agonist (SAG). 24 hours later, cells were fixed and stained with 
antibodies directed towards GLI3, PERICENTRIN as basal body marker, ARL13B as 
ciliary marker, and DAPI as a nuclear marker. GLI3 ciliary intensity was calculated at 
cilia tip and along the axoneme and corrected to background staining using ImageJ 
software. As expected, the immunofluorescence analysis of both total cilia intensity 
of GLI3 and cilia tip GLI3 had no significant differences in ARL3 mutant and control 
fibroblasts Figure 5.11. 
We reported no defect in GLI3 ciliary localisation confirming that ARL3 Arg149His 
mutation doesn’t disturb ciliary Hedgehog signalling pathway.     
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Figure 5.11 Lack of disruption of GLI3 localisation in cilia axoneme and tip in 
ARL3 mutant fibroblasts  
Fibroblasts from affected individuals in family 2 (II:5, II:4, II:1) and controls (I:1, I:2, 
II:3) were treated with 100 nM SAG then fixed and stained with antibodies directed 
towards ARL13B (red), GLI3 (green), PERICENTRIN (magenta) and DAPI (blue) as 
a nuclear marker. Representative single channel images are shown for ARL13B, 
GLI3 and PERICENTRIN as well as overlay images at low power (scale bar = 10 
µm) and zoomed (scale bar = 5 µm). 
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Figure 5.12  Quantification of ciliary localization of GLI3  
(A) Quantification of ciliary localisation of GLI3 is shown (n >35 for each group, n.s. 
not significant, ANOVA).  
(B) Quantification of ciliary tip localisation of GLI3 is shown (n >35 for each group, 
n.s. not significant, ANOVA).   
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5.2.5. siRNA mediated knockdown of ARL3 in WT HUREC 
JBTS phenotype in family 2 involved renal manifestation in the form of multicystic 
kidney. To further investigate whether the role of ARL3 in ciliary cargo protein 
trafficking is tissue specific, we sought to study its function on kidney cells model. 
Human Urine derived Renal Epithelial Cell (HUREC) culture is a non-invasive way of 
isolating human renal tubular epithelial cells from both adults and children and 
serving as an excellent model to study ciliopathies (Srivastava et al., 2017, 
Ajzenberg et al., 2015). HUREC were cultured from age-matched donor not known 
to have kidney problems. Cells were obtained from 100 ml urine sample from wild-
type (WT) donor and plated in 12 well cell culture plates. HUREC proliferate and 
form monolayer 2D culture within a period of 14 days. HUREC can be used in 
experiments when reaching confluency of 70-80% and lasts up to 6 passages.  
 
 
 
Figure 5.13 Non-invasive method of isolating HUREC from urine sample  
Urine collected from patients and healthy donors was processed within 4 hours of 
collection. The resulting pallets of cells were plated and grown in 12 well plate. The 
epithelial cells begin to appear on day 5 and can be used for passaging or 
experiments after reaching 80- 90% confluence.  
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We conducted a small interfering RNA (siRNA) mediated ARL3 knockdown 
experiment on WT HUREC. The knockdown was confirmed by gene expression 
analysis using RT PCR of HUREC obtained from siRNA mediated knockdown of 
ARL3 (siARL3) and siRNA mediated control (siCtrl), the experiment demonstrated 
loss of ARL3 mRNA. Figure 5.14. Once again, immunofluorescent microscopy used 
to study the structural and the functional of the treated HUREC.  Consistent with 
morphologically normal cilia in ARL3-mutant fibroblasts, no structural defect seen 
siARL3 HUREC. Since primary cilia tissue specific, the cilia length of siARL3 and 
siCtrl HUREC were analysed, and no significant difference in cilia length reported 
Figure 5.15. Next, we determined the localisation of GSF cargo proteins (INPP5E 
and NPHP3) in siARL3 HUREC compared to siCtrl HUREC. In agreement with our 
previous results on ARL3-mutant fibroblasts cilia, immunofluorescent microscopy 
analysis revealed significant reduction in ciliary content of both INPP5E (Figure 5.16 
and Figure 5.17) and NPHP3 (Figure 5.18 and Figure 5.19). 
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Figure 5.14 ARL3 gene expression analysis using quantitative real time PCR to 
demonstrate the effect of ARL3 knockdown experiment on HURECs  
 
 
 
 
 
Figure 5.15 Quantification of cilia length siRNA mediated ARL3 knockdown in 
HUREC 
Quantification of cilia length in siARL3 and siCtrl groups (n.s. not significant, 
unpaired t test, >90 cilia for each group). 
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Figure 5.16 Immunofluorescence analysis WT HUREC cilia treated with ARL3 
siRNA demonstrate decrease of cilia INPP5E content 
siRNA mediated knockdown of ARL3 leads to reduction in ciliary content of INPP5E 
in comparison with siCtrl. HURECs were fixed and stained with antibodies directed 
towards ARL13B (red), INPP5E (green) and DAPI (blue) as a nuclear marker. 
Representative individual images are shown for ARL13B and INPP5E as well as 
overlay images at high power. Scale bar = 5 µm.  
 
 
Figure 5.17 Quantification of ciliary localization of INPP5E in siRNA mediated 
ARL3 knockdown in HUREC 
Quantification of ciliary localization of INPP5E in siARL3 and siCtrl groups (∗∗∗∗p < 
0.0001, unpaired t test, n > 45 cilia for each group). 
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Figure 5.18 Immunofluorescence analysis WT HUREC cilia treated with ARL3 
siRNA demonstrate decrease of cilia NPHP3 content 
siRNA mediated knockdown of ARL3 leads to reduction in ciliary content of NPHP3 
in comparison with siCtrl. HURECs were fixed and stained with antibodies directed 
towards ARL13B (red), INPP5E (green), PERICENTRIN (magenta) and DAPI (blue) 
as a nuclear marker. Representative individual images are shown for ARL13B, 
NPHP3 and PERICENTRIN as well as overlay images at high power. Scale bar = 5 
µm. 
 
Figure 5.19 Quantification of ciliary localization of NPHP3 in siRNA mediated 
ARL3 knockdown in HUREC 
Quantification of ciliary localization of INPP5E in siARL3 and siCtrl groups (∗∗∗p = 
0.0007, unpaired t test, n > 45 cilia for each group). 
ARL13B
siCtrl
NPHP3
siARL3
DAPIPERICENTRIN
siA
RL
3
siC
trl
0
500
1000
1500
2000
To
ta
l c
ili
a 
NP
HP
3
 in
te
ns
ity
 (a
u)
***
  
112 
 
5.3. Discussion  
ARL3 cycles between inactive-GDP bound and active-GTP bound forms. Activated 
ARL3 binds to cargo-carrier complex to induce conformational changes leading to 
the release of the ciliary cargo. In the cilia, ARL3 gets activated by the exclusive 
presence of its  GEF ARL13B, while the presence of ARL3 GAP, RP2,  outside the 
cilia creates an ARL3GTP gradient across the transition zone acting like a driving 
force to transport the lipidated cargo protein to the cilia (Gotthardt et al., 2015).  
Our results have shown the essential implication of ARL3 Arg149 residue for the 
regulation of sorting and transport of ciliary cargo protein to the cilia. By employing 
crystallography to elucidate the structural basis for the interaction, the structure 
showed the evolutionarily conserved and the ARL3 Arg149 residue (R148 [Arg148] 
in CrARL3) is located in the loop region between the α4 and β6 domains of ARL3 
that directedly interact with the ARL13B Glu88 residue located in the switch II 
domain of ARL13B (E86 [Glu86] in C. reinhardtii ARL13B [CrARL13B]) during 
interaction interface to form ARL13B-ARL3 complex described by Gotthardt et al. 
(2015). Figure 5.20. A marked decrease in GEF activity assay was detected during 
the interaction of the exact ARL3 Arg149 mutant residue with ARL13B compared to 
wild type, indicating disruption in the cargo release function of ARL13B-ARL3 
complex.  
We studied the ciliary phenotype of ARL3 Arg149His patient derived fibroblasts, as 
changes in cilia length or structure can reflect the ciliogenesis process.  As we 
expected from previous reports, the detected ARL3 Arg149 mutant variant exhibit no 
significant change in the frequency of ciliation, cilia length or morphology when 
compared to healthy carriers and wildtype fibroblasts. Our immunofluorescence 
microscopy results were confirmed with scanning electron microscopy. However, 
Zhang et al. (2016) reported an excess of ARL3-GDP may affect ciliogenesis 
indirectly by titrating out its GEF or other protein involved in ciliogenesis, our data 
contradict their conclusion.  
Moreover, we examined the allosteric release function of the ARL3 Arg149His on 
lipidated protein trafficking to the cilia on patients derived fibroblasts. Myristoylated 
proteins and prenylated proteins are lipid modified proteins required an interaction 
with carrier protein to prevent their interaction with plasma membrane and gain a 
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soluble transient at ciliary fate and transition zone  (Hu et al., 2010). INPP5E an 
example of prenylated ciliary protein, involved in ciliogenesis and known to cause 
JBTS1 when its encoded gene is mutated, binds to its carrier PDE6D to form a 
solubilised ciliary cargo-carrier complex (Humbert et al., 2012). NPHP3 an example 
of myristoylated ciliary protein, localised to cilia and involved in signalling pathways, 
binds to its carrier UNC119 (Wright et al., 2011). In the wild-type cilia, ARL3 is GTP 
bound an active allowing the docking of ciliary cargo INPP5E/NPHP3 and the 
release of its carrier PDE6D/UNC119. Thereby, the lipid moiety of cargo protein will 
be exposed and associate with the ciliary membrane and localise to the cilia. 
Based on the above mentioned model of trafficking, we speculated that the ciliary 
localisation of ciliary cargo protein to be reduced in ARL3 Arg149His cilia. As 
expected, the immunofluorescence microscopy analysis of total cilia INPP5E/NPHP3 
protein content in ARL3 mutant cilia confirmed a significant loss of INPP5E/NPHP3 
content compared to control cilia. We also confirmed that the ciliary Sonic hedgehog 
pathway is not disturbed by ARL3 Arg149His variant.  
To further explain the renal phenotype of ARL3 mutation in the second JBTS family 
(ARL3 Arg149Cys), we sought to determine the effect of ARL3 knockdown on wild-
type HUREC. Interestingly, total loss of function mutation of ARL3 had the same 
effect as the missense mutation ARL3. Our data showed that siRNA mediated 
knockdown of ARL3 cilia replicated the phenotype of ARL3 Arg149His patient 
fibroblasts. No significant change found in cilia length and a marked loss of both 
ciliary content of cargo protein INPP5E and NPHP3.  
We conclude that ARL3 mutation disturb the ciliary protein composition by disrupting 
ARL13B-ARL3 interaction manifesting in JBTS35. Figure 5.21  
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Figure 5.20 The CrArl13B-CrArl3 complex  
Schematic representation of residues located in the interaction interface of the 
CrArl13B-CrArl3 complex. The dashed lines illustrate the hydrogen bonds between 
residues and red lines illustrate the salt bridges. The red circles indicate the Cr 
analogue of the detected human ARL3 Arg149 residue.  Adapted from (Gotthardt et 
al., 2015) 
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Figure 5.21 Model of GSF-cargo release in cilia with wild-type ARL3 versus 
R149H ARL3 
ARL13B assists ARL3 in cilia to exchange its bound GDP to GTP. The specific 
localisation of ARL13B in the cilia creates a high concentration of ARL3-GTP. ARL3-
GTP in turn can release the cargo bound to its cognate GSF and results in ciliary 
localisation. Mutant ARL3 (R149H) is not able to interact with ARL13B and the 
ARL3GTP concentration is therefore low in the cilia, which results in inefficient 
release of GSF cargo in the cilia. 
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Chapter 6 Final discussion and concluding remarks  
6.1. Lessons learned from the Renal-Genetic family clinic 
The constant expanding list of genotypes and phenotypes associated with inherited 
renal disorders make the correct identification of inherited renal syndromes and 
disorders quite challenging. NGS technologies have helped speed up the discoveries 
of novel genes in inherited renal disorders, an allow known genetic disorders to be 
screened rapidly, for example the successful multigene panel to screen for Alport 
syndrome (Artuso et al., 2012). NGS gene panels have recently been applied to 
patients with atypical kidney disease phenotypes for genetic diagnosis (Bullich et al., 
2018). 
Whole exome sequencing (WES) is a proven approach to identify novel genes 
causing inherited renal disorders, however it is hindered by the high numbers of 
variants detected when all the exons-coding sequences in human genome are 
analysed.  Such obstacles can be overcome by limiting the analysis to smaller 
regions of the exome detected by means of linkage analysis or homozygosity 
mapping (MacArthur et al., 2014).  
We found that the practice of a multidisciplinary renal genetic clinic provides added 
value and improved patient care though identifying the precise molecular genetic 
diagnosis Figure 6.1. Despite all the challenges, applying highly advanced NGS 
technologies will certainly improve diagnosis efficiency, prognosis, and genetic 
counselling for patients in clinical practice every day. Moreover, following a genetic 
diagnosis, patients are often able to receive better healthcare and the cost of 
additional investigation maybe reduced. The implementation of genomic medicine 
throughout the NHS services is the core vision of Genomics England.  
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Figure 6.1 Lessons learnt from multidisciplinary renal-genetic family clinic 
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6.2. ARL3 mutations cause Joubert syndrome by disrupting ciliary protein 
composition    
ARL3 is a highly conserved gene, and its encoded soluble small G protein is found in 
all ciliated organisms, several human tissues and tumour cell lines (Cavenagh et al., 
1994). We present ARL3 as a ciliopathy and JBTS associate gene.  ARL3 role in 
ciliogenesis and axoneme formation was first noted by studying the Leishmania 
homolog of ARL3, LdARL-3A, where it is found to be crucial for flagellum formation 
(Cuvillier et al., 2000). A germline mutation in mice leading to knockout of Arl3 gave 
rise to classic syndromic ciliopathy phenotype similar to that found in ARPKD. These 
Arl3-/- mice developed cysts formation in kidneys, liver and pancreas, pancreatic 
hypoplasia, ductal plate malformation, retinal dystrophy in addition to photoreceptors 
degeneration (Schrick et al., 2006). Arl3-/- manifestations were severe and mutant 
mice failed to thrive beyond postnatal week 3; the nonsense phenotype in these 
mice seems much more detrimental than the missense phenotype we reported in our 
JBTS families. We hypothesize that nonsense ARL3 mutation in human may cause a 
distinct ciliopathy phenotype as severe as the murine phenotype and may be 
perinatally lethal, just like Meckel syndrome, perhaps in part explaining its rarity.  
The previously reported ARL3 mutation in human was not linked to a human 
multisystem ciliopathy disorder. A heterozygous missense variant of ARL3 was 
reported by Strom et al. (2016) in a Caucasian family with non-syndromic retinitis 
pigmentosa. The ARL3 missense variant (p.Tyr90Cys) was identified in three 
affected individuals, appeared de novo, and transmitted in an autosomal dominant 
fashion. ARL3 Tyr90Cys was rare and found to be pathogenic by in silico prediction 
tools. A second allele within ARL3 was not identified and no further mechanistic 
evaluation was carried out. On the other hand, we have identified pathogenic biallelic 
variants in ARL3 in two different families with JBTS. ARL3 mutations fully segregated 
with a classical JBTS phenotype, in addition to the retinal changes. We present 
strong evidence that biallelic ARL3 deleterious variants are sufficient to cause JBTS. 
Mutations in the genes encoding ARL3 effectors (interaction partners) ARL13B and 
PDE6D are also known to cause JBTS. Mutations in ARL13B  (JBTS8) led to classic 
neurodevelopmental phenotype without reported renal involvement (Cantagrel et al., 
2008). Thomas et al. (2015) identified another variant in ARL13B that extended the 
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phenotypic presentation of JBTS8 to include retinal defects and obesity. Mutation in 
PDE6D were found to cause JBTS22, in a consanguineous family of 3 affected 
siblings (Thomas et al., 2014). The neurodevelopmental phenotype was associated 
with hands and feet post axial polydactyly, coloboma, facial dysmorphism, retinal 
dysplasia or renal hypoplasia. Moreover, the genes INPP5E and NPHP3 encoding 
the disrupted ciliary cargo proteins (INPP5E and NPHP3) we have identified may 
also be responsible for JBTs phenotypes. Mutations in INPP5E can cause JBTS1, in 
a cohort of JBTS patients that presented with neurodevelopmental phenotypes with 
retinopathy in a subgroup, no polydactyly or renal disease reported (Bielas et al., 
2009). However, 10% of JBTS patient with INPP5E mutation can develop renal 
manifestations (Kroes et al., 2016). On the other hand, mutation in NPHP3 were first 
found to cause adolescent nephronophthisis, a progressive form of renal failure , in a 
large Venezuelan family (Omran et al., 2000). Later NPHP3 phenotypes expanded to 
include infantile nephronophthisis, lethal neonatal nephronophthisis and renal 
hepatic pancreatic dysplasia and Meckel syndrome (Tory et al., 2009, Simpson et 
al., 2009, Bergmann et al., 2008).  
Interestingly, ARL3 role in releasing lipid modified protein extends beyond the cilium 
to the immune synapse (Stephen et al., 2018). T cells lack the presence of cilia, 
however, similarities between cilia and the immune synapses have been clearly 
recognized (de la Roche et al., 2016). Lymphocyte- specific tyrosine protein kinase 
(LCK) initiate the interaction at the immune synapse between T cells and antigen-
presenting cells (APC). LCK undergoes post-translational myristoylation to facilitate 
plasma membrane localisation and require a solubilising carrier for proper trafficking 
to immune synapse. Stephen et al. reported that trafficking of lipid modified LCK is 
mediated by UNC119A to the immune synapse where its release by ARL3-GTP. 
Their work has also identified the endogenous localization of ARL3 GEF, ARL13B, at 
the T cell membrane and outside the cilia (Stephen et al., 2018).  
Ciliopathies in general and JBTS in particular exhibit an overlapping phenotype as 
well as genotypes. Such overlap can be explained by the fact that proteins coded by 
ciliary genes function through an interaction networking and don't work in isolation 
(Humbert et al., 2012). We propose ARL3 as a JBTS causing gene and a novel hub 
in a network of ciliopathy causing genes and ARL3 is now recognized as JBTS35  
https://www.omim.org/phenotypicSeries/PS213300  (Alkanderi et al., 2018). 
  
120 
 
6.3. Future directions  
We have identified two missense mutations of ARL3 at the same amino acid Arg149 
but resulting in two different amino acids changes and eventually leading to different 
phenotypic presentation in two different JBTS families. Phenotypic differences may 
be related to differences in the genetic background of both families. However, this 
phenotypic heterogeneity requires further explanation and understanding of the 
ciliopathy pathways involved. Future work will aim to develop mouse models to 
characterise the two different mutations identified in ARL3 (Arg149His and 
Arg149Cys) using CRISPR/Cas9. Together with our collaborators at the Beatson 
Institute, University of Glasgow, we aim to compare Arl3 mutant mice with Arl13b 
mutant mice to further study the ARL3-ARL13b interaction and the GEF role in the 
release of ciliary cargo proteins.    
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